US20050124844A1 - Combination ionizing radiation and radiosensitizer delivery devices and methods for inhibiting hyperplasia - Google Patents
Combination ionizing radiation and radiosensitizer delivery devices and methods for inhibiting hyperplasia Download PDFInfo
- Publication number
- US20050124844A1 US20050124844A1 US11/009,501 US950104A US2005124844A1 US 20050124844 A1 US20050124844 A1 US 20050124844A1 US 950104 A US950104 A US 950104A US 2005124844 A1 US2005124844 A1 US 2005124844A1
- Authority
- US
- United States
- Prior art keywords
- radiosensitizer
- balloon
- ionizing radiation
- catheter
- hyperplasia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1282—Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/105—Balloon catheters with special features or adapted for special applications having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/1052—Balloon catheters with special features or adapted for special applications for temporarily occluding a vessel for isolating a sector
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/1097—Balloon catheters with special features or adapted for special applications with perfusion means for enabling blood circulation only while the balloon is in an inflated state, e.g. temporary by-pass within balloon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/002—Packages specially adapted therefor ; catheter kit packages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/1011—Multiple balloon catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
- A61N5/1002—Intraluminal radiation therapy
- A61N2005/1003—Intraluminal radiation therapy having means for centering a radioactive source within the lumen, e.g. balloons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
- A61N5/1002—Intraluminal radiation therapy
- A61N2005/1004—Intraluminal radiation therapy having expandable radiation sources
Definitions
- the present invention relates generally to medical devices and methods for inhibiting restenosis in a blood vessel after an initial treatment for opening a stenotic region in a blood vessel. More particularly, the present invention relates to combination radiation and radiosensitizer delivery devices for inhibiting hyperplasia following balloon angioplasty and other interventional treatments.
- PTA percutaneous transluminal angioplasty
- a catheter having an expansible distal end usually in the form of an inflatable balloon, is positioned in the blood vessel at the stenotic site. The expansible end is expanded to dilate the vessel to restore adequate blood flow beyond the diseased region.
- Other procedures for opening stenotic regions include directional atherectomy, rotational atherectomy, laser angioplasty, stenting, and the like. While these procedures have gained wide acceptance (either alone or in combination, particularly PTA in combination with stenting), they continue to suffer from significant disadvantages.
- a particularly common disadvantage with PTA and other known procedures for opening stenotic regions is the frequent occurrence of restenosis.
- Restenosis refers to the re-narrowing of an artery after an initially successful angioplasty. Restenosis afflicts approximately up to 50% of all angioplasty patients and is the result of injury to the blood vessel wall during the lumen opening angioplasty procedure. In some patients, the injury initiates a repair response that is characterized by smooth muscle cell proliferation referred to as “hyperplasia” in the region traumatized by the angioplasty. This proliferation of smooth muscle cells re-narrows the lumen that was opened by the angioplasty within a few weeks to a few months, thereby necessitating a repeat PTA or other procedure to alleviate the restenosis so that blood perfusion may be restored.
- Radioisotope radiation and drug therapy following PTA for the inhibition of hyperplasia
- Drug therapy infuses or releases a drug through a catheter or from a stent
- intravascular radiotherapy may configure catheters, guidewires, and stents to position a solid radioisotopic source (such as a wire, strip, pellet, seed, bead, or the like).
- a solid radioisotopic source such as a wire, strip, pellet, seed, bead, or the like.
- Biodegradable materials are described in U.S. Pat. Nos. 5,876,452; 5,656,297; 5,543,158; 5,484,584; 4,897,268; 4,883,666; 4,832,686; and 3,976,071.
- the present invention provides improved devices, methods, and kits for inhibiting restenosis and hyperplasia after intravascular intervention.
- the present invention provides controlled radiosensitizer delivery in combination with ionizing radiation delivery to selected locations within a patient's vasculature to reduce and/or inhibit restenosis and hyperplasia rates with increased efficacy.
- the methods and apparatus of the present invention can significantly reduce dose concentrations of radiosensitizers and/or radiation within the vessel wall while delivering sufficiently uniform radiation dosages and promoting endothelialization of the vessel wall.
- intravascular intervention includes a variety of corrective procedures that may be performed to at least partially resolve a stenotic condition.
- the corrective procedure will comprise balloon angioplasty.
- the corrective procedure could also comprise atherectomy, rotational atherectomy, laser angioplasty, stenting, or the like, where the lumen of the treated blood vessel is enlarged to at least partially alleviate a stenotic condition which existed prior to the treatment.
- the corrective procedure could also involve coronary artery bypass, vascular graft implantation, endarterectomy, or the like.
- controlled radiosensitizer delivery it is meant that a predetermined amount of the radiosensitizer is released or delivered at a predetermined rate to a blood vessel. Typically, such controlled delivery maintains a steady-state concentration of the radiosensitizer in a vascular environment within a desired therapeutic range of time, e.g. hours, days, weeks, or in some cases months.
- a combination radiation and radiosensitizer delivery catheter for inhibiting hyperplasia generally comprises a catheter body having a proximal end and distal end, a ionizing radiation source coupleable to the catheter body for applying a radiation dose to a body lumen, and means coupleable to the catheter body or the radiation source for releasing a radiosensitizer to the body lumen.
- the body lumen may be any blood vessel in the patient's vasculature, including veins, arteries, aorta, and particularly including peripheral and coronary arteries.
- the ionizing radiation source is preferably an x-ray tube since it provides many advantages, such as convenient dosing where the source may be easily turned on and off, minimal disposal problems, and the like.
- the ionizing radiation source may comprise a radioisotope, such as a solid radioisotopic source (e.g., wire, strip, pellet, seed, bead, or the like), or a liquid radioisotopic filled balloon.
- the balloon has been specially configured to prevent leakage of the radioisotopic material from the balloon into the body lumen or blood stream.
- the ionizing radiation source may comprise a receptacle in the catheter body for receiving radioisotopic materials like pellets or liquids.
- the radioisotopic material may be selected to emit alpha, beta, or gamma radiation.
- alpha and beta radiation are preferred since they may be quickly absorbed by surrounding tissue and will not penetrate substantially beyond the wall of the body lumen being treated. Accordingly, incidental irradiation of the heart and other organs adjacent to the treatment region can be substantially eliminated.
- the means may comprise a source of at least one radiosensitizer selected from the group consisting of taxol, nisonidazole, metronidazole, etanidazole, 5-fluorouracil, texaphyrin, C225 (an anti-EGFR monoclonal antibody), and cyclooxygenase-2 inhibitor.
- the radiosensitizer may also be a prodrug (e.g., precursor substances that are converted into an active form in the body) of any of the above described radiosensitizers.
- the means comprises a source of taxol, incorporated in a solution with polyoxyethylated castor oil and dehydrated alcohol.
- the radiosensitizer may also be attached or encapsulated in a lipid or surfactant carrier.
- radiosensitizers reduces and/or inhibits restenosis and hyperplasia rates with increased efficiency.
- the radiation will provide an immediate inhibition of cell proliferation while the radiosensitizers, which may be released over relatively long periods of time, e.g. days, weeks, or in some cases months, will provide prolonged inhibition.
- the delivery of radiosensitizers is particularly advantageous since radiosensitizers provide synergistic enhancement to radiation effects, such as enhancing apoptosis of proliferative smooth muscle cells and/or minimizing smooth muscle cell proliferation.
- radiosentizers may enhance the effect of radiation by increasing the cell cycle in which proliferative smooth muscle cells are most susceptible to radiation.
- radiosentizers may inhibit radiation DNA damage repair of proliferative smooth muscle cells to further reduce and/or inhibit restenosis and hyperplasia. It will be appreciated that many of the above described radiosensitizers may also promote endothelialization of the vessel wall, which is needed for healing. Furthermore, a combined balance of both therapies allows for reduced dosages/concentrations of radiation and/or radiosensitizers in the body lumen, as compared to relying on a single therapy with an increased dosage which may not be as effective.
- radiosensitizers there are a number of means available for releasing any of the above described radiosensitizers.
- Conventional intravascular delivery devices typically comprise a source of the radiosensitizer, that may be external or internal to the device, and means for controlled radiosensitizer release to the body lumen.
- Such means may comprise a porous material which contains the radiosensitizer, wherein the radiosensitizer may elute out at a controlled rate from the pores.
- Such means may alternatively comprise a matrix, membrane, barrier, or coating which includes the radiosensitizer.
- a matrix comprises a rate controlling material wherein the rate controlling material controls the rate at which the radiosensitizer is released from the matrix.
- Such means may further comprise an infusion lumen for radiosensitizer release or a radiosensitizer eluting stent or graft. Still further, such means may comprise a reservoir containing the radiosensitizer and a cover over the reservoir. Typically, the cover comprises a matrix, membrane, or barrier which in turn controls the rate at which the radiosensitizer is released from the reservoir.
- the means for releasing the radiosensitizer may comprise at least one microporous balloon on the catheter body. It is presently preferred that such a one balloon embodiment be employed in the coronary arteries as these vessels are relatively limited in size.
- the microporous balloon is usually inflated with any of the above described radiosensitizers and the radiosensitizer is released at a controlled rate from the microporous balloon by elution from pores.
- the microporous balloon is preferably elastic and made from nylon, Pebax, polyurethane, or like materials.
- the ionizing radiation source is typically positionable within the balloon.
- the means for releasing the radiosensitizer may comprise a matrix, membrane, barrier, or coating formed over at least a portion of at least one balloon on the catheter body.
- the radiosensitizer may be disposed in the matrix or on a surface of the balloon beneath the matrix and the ionizing radiation source is typically positionable within the balloon.
- the matrix will typically comprise a rate controlling material, wherein the rate controlling material controls the rate at which the radiosensitizer is released from or through the matrix.
- the rate controlling material may be composed of degradable, partially degradable, nondegradable polymer, synthetic, or natural material.
- the matrix may degrade by bulk degradation, in which the matrix degrades throughout, or preferably by surface degradation, in which a surface of the matrix degrades over time while maintaining bulk integrity, to allow release of the radiosensitizer.
- a nondegradable matrix may release the radiosensitizer by diffusion through the matrix.
- the rate controlling material may be porous so as to allow elution of the radiosensitizer from pores.
- the means may comprise a matrix, membrane, barrier, or coating formed over at least a portion of a radioisotopic balloon, wherein the radiosensitizer is in or beneath the matrix.
- the matrix may allow for controlled release of the radiosensitizer into the body lumen in a variety of forms as described above. Additionally, the liquid radioisotope filled balloon will serve as the ionizing radiation source.
- any of the above described balloons may further comprise perfusion threading on an outer surface to allow for blood perfusion.
- Such threading may form a spiral, helical, or angled pattern on the balloon surface.
- the catheter of the present invention may alternatively be equipped with a perfusion lumen/port to permit blood flow past the balloon when inflated.
- a combined radiation and radiosensitizer delivery catheter for inhibiting hyperplasia generally comprises a catheter body having an infusion lumen for releasing a radiosensitizer, a pair of axially spaced apart balloons on the catheter body, and an ionizing radiation source.
- the ionizing radiation source applies a radiation dose between the axially spaced apart balloons while the infusion lumen releases the radiosensitizer therein.
- such a two balloon catheter embodiment be employed in the peripheral arteries as such a structure may help center and correctly position the radiation source in the peripheral vessels, provide a pocket for drug delivery, and aid in uniform radiation dosimetry, as described in greater detail in co-pending U.S. patent application Ser. No. 09/653,444, assigned the assignee herein, the full disclosure of which is incorporated herein by reference.
- One method includes releasing a radiosensitizer at a target region within the body lumen and directing ionizing radiation at the target region, wherein the radiosensitizer and radiation combine to inhibit hyperplasia.
- the “target region” will be a length within a blood vessel which is at risk of hyperplasia, typically as a result of the initial intravascular intervention(s).
- the method may further comprise inflating a balloon at the target region, wherein the radiosensitizer is released from the balloon.
- the balloon may be inflated with the radiosensitizer so that the radiosensitizer is released from an interior of the balloon through pores or the radiosensitizer may be released from a surface of the balloon through a rate controlling matrix.
- the method may optionally comprise isolating the target region, wherein the radiosensitizer is released into the isolated region.
- the isolating may comprises inflating a pair of axially spaced apart balloons or expanding a pair of axially spaced apart mechanical barriers.
- the ionizing radiation source is positioned within the balloon or the isolated target region.
- the ionizing radiation source may comprise an x-ray tube, wherein positioning generally comprises energizing the x-ray tube and translating the x-ray tube to traverse the target region.
- the ionizing radiation source may comprise a radioisotope or a receptacle in the catheter body.
- the ionizing radiation source generally applies a total radiation dose in a range from about 4 Gy to 24 Gy, preferably from 14 Gy to 20 Gy.
- the total amount of radiosensitizer released will typically depend on the specific radiosensitizer being delivered.
- the radiation dose and radiosensitizer release may additionally be carried out simultaneously or sequentially.
- kits comprising a catheter and instructions on how to use the catheter are provided.
- the kit may also include a source of the radiosensitizer.
- the catheter may comprise any of the delivery structures described herein, while the instructions for use will generally recite the steps for performing one or more of the above described methods.
- the instructions will often be printed, optionally being at least in-part disposed on packaging.
- the instructions may alternatively comprise a videotape, a CD-ROM or other machine readable code, a graphical representation, or the like showing any of the above described methods.
- FIG. 1 is a plan view of an apparatus according the present invention.
- FIG. 2 is a cross sectional view of the apparatus of FIG. 1 within a blood vessel.
- FIGS. 3A-3C illustrate various means for releasing a radiosensitizer.
- FIG. 4 illustrates a distal tip of the catheter of FIG. 1 with a spiral perfusion balloon.
- FIG. 5 is a plan view of an alternate embodiment of an apparatus according to the present invention.
- FIG. 6 is a cross sectional view of the apparatus of FIG. 5 within a blood vessel.
- FIG. 7 is a plan view of another alternate embodiment of an apparatus according to the present invention.
- FIG. 8 is a cross sectional view of the apparatus FIG. 7 within a blood vessel.
- FIG. 9 illustrates a combination radiation and radiosensitizer delivery kit including the apparatus of FIG. 1 and instructions for its use.
- the present invention provides improved devices, methods, and kits for inhibiting restenosis and hyperplasia after intravascular intervention.
- the present invention provides controlled radiosensitizer delivery in combination with ionizing radiation delivery to selected locations within a patient's vasculature to reduce and/or inhibit restenosis and hyperplasia rates with increased efficacy.
- FIGS. 1 and 2 illustrate a combination radiation and radiosensitizer delivery catheter 10 constructed in accordance with the principles of the present invention.
- the combination radiation and radiosensitizer delivery catheter 10 comprises a shaft or body 12 having a proximal end 14 and distal end 16 , a radiation source 22 coupleable to the distal end 16 of the catheter body 12 for applying a radiation dose to a target region 34 in a body lumen 32 , and means coupleable to the distal end 16 of the catheter body 12 for releasing a radiosensitizer 19 to the target region 34 .
- the proximal end 14 of shaft 12 includes a guidewire lumen luer fitting 24 and a balloon luer fitting 26 .
- the guidewire luer fitting 24 is in fluid communication with a guidewire/perfusion lumen that is in turn in fluid communication with perfusion ports 28 .
- Perfusion ports 28 are well known in the art as a means of permitting some blood flow past a balloon 18 that is inflated or otherwise blocking a blood vessel.
- the balloon luer fitting 26 is in fluid communication with a balloon inflation lumen that is in turn in fluid communication with balloon 18 . It will be appreciated that the following depictions are for illustration purposes only and does not necessarily reflect the actual shape, size, or distribution of the delivery catheter 10 .
- the body lumen 32 may be any blood vessel in the patient's vasculature, including veins, arteries, aorta, and particularly including peripheral and coronary arteries. It will be appreciated that the present invention may also find use in body lumens 32 other than blood vessels. For example, the present invention may be applied to many internal corporeal tissue organs, such as organs, nerves, glands, ducts, and the like.
- the radiation source 22 may be a radioisotope or a receptacle for receiving radioisotopic materials.
- Radioisotope sources may comprise a point source, wire, strip, pellet, seed, bead, liquid radioisotope balloon, and the like, selected to emit alpha, beta, or gamma radiation.
- the radiation source 22 is an x-ray tube, as illustrated in FIGS. 1 and 2 .
- the x-ray tube 22 can be isotropic, such as a transmission anode, or non-isotropic, such as an opaque anode.
- the x-ray will typically operate at an energy in the range from 18 kV to 28 kV. Exemplary x-ray sources are described in co-pending application Ser. No.
- Suitable radiosensitizers 19 include taxol, misonidazole, metronidazole, etanidazole, 5-fluorouracil, texaphyrin (e.g., XcytrinTM sold commercially by Pharmacyclics, and RSR13TM sold commercially by Allos Therapeutics), C225, and cyclooxygenase-2 inhibitor.
- the radiosensitizer 19 may also be a prodrug of any of the above described radiosensitizers.
- the radiosensitizer 19 comprises taxol, alone or in combination with any of the other radiosensitizers described above.
- the total amount of radiosensitizer released depends on the specific radiosensitizer being delivered as well as on the level and amount of vessel injury and the total amount of radiation applied.
- taxol may be released at levels of 130 micrograms/cm 3 or less.
- radiosensitizers 19 and radiation 22 reduces and/or inhibits restenosis and hyperplasia rates with increased efficiency.
- the delivery of radiosensitizers 19 is particularly advantageous since radiosensitizers provide synergistic enhancement to radiation effects, such as enhancing apoptosis of proliferative smooth muscle cells and/or minimizing smooth muscle cell proliferation. It will be appreciated that many of the above described radiosensitizers 19 may also promote endothelialization of the vessel wall, which is needed for healing.
- a combined balance of both therapies allows for reduced dosages/concentrations of radiation and/or radiosensitizers in the body lumen, as compared to relying on a single therapy with an increased dosage.
- the means for releasing the radiosensitizer may comprise at least one microporous balloon 18 on the catheter body 12 . It is presently preferred that such a one balloon embodiment be employed in the coronary arteries.
- the microporous balloon 18 is usually inflated with any of the above described radiosensitizers 19 via the balloon luer fitting 26 .
- the radiosensitizer 19 is then released from the microporous balloon 18 by elution from pores.
- the microporous balloon 18 is preferably elastic and made from nylon, Pebax, polyurethane, or like materials, and may be an integral extension of the catheter body 12 , or attached to the distal end 16 of the catheter body 12 by suitable adhesives, heat welding, or the like.
- the catheter body 12 may be formed from conventional materials, such as polyethylenes, polyimides, and copolymers and derivatives thereof
- alternative means for releasing the radiosensitizer may comprise a matrix 21 formed over at least a portion of a balloon 18 ′ on the catheter body 12 .
- the matrix 21 will typically comprise a rate controlling material, wherein the rate controlling material controls the rate at which the radiosensitizer 19 is released from or through the matrix 21 .
- the radiosensitizer 19 may be disposed on a surface of the balloon 18 ′, as illustrated in FIG. 3B , or within the matrix 21 , as illustrated in FIG. 3C .
- the balloon 18 ′ may be inelastic or preferably elastic, and is preferably made of polyurethane, Pebax, or other medical grade elastomeric material suitable for constructing puncture-resistant elastic balloons. Balloon 18 ′ is generally inflatable via the balloon luer fitting 26 .
- the rate controlling material may comprise degradable, partially degradable, nondegradable polymer, synthetic, or natural material.
- the matrix may degrade by bulk degradation, in which the matrix degrades throughout, or preferably by surface degradation, in which a surface of the matrix degrades over time while maintaining bulk integrity, to allow release of the radiosensitizer. Alternatively, a nondegradable matrix may release the radiosensitizer by diffusion through the matrix.
- the rate controlling material may be porous so as to allow elution of the radiosensitizer from pores.
- the radiosensitizer 19 and/or the matrix 21 are coated, sprayed, dipped, deposited, or painted on the balloon surface.
- any of the above described balloons may further incorporate a perfusion threading or band 36 affixed to an outer surface of the balloon 18 by adhesion bonding, heat welding, fasteners, or the like.
- Threading patterns may be spiral (as shown in FIG. 4 ), helical, or angled.
- the threading 36 may be formed from polymer materials and may aid in perfusion so as to permit blood flow past the balloon when inflated.
- an appropriately sized catheter 10 as illustrated in FIGS. 1 and 2 is advanced via a guidewire 30 within a blood vessel segment 32 having a treatment region 34 so that the radiation source 22 (which is positionable within the balloon 18 ) and the at least one balloon 18 are positioned at the target region 32 .
- the treatment region 34 has previously been enlarged by balloon angioplasty or other procedures such that atherosclerotic plaque has been radially compressed by expansion of the balloon portion of an angioplasty device (not shown).
- the balloon 18 (as shown in FIG. 2 ) is inflated in the blood vessel via the balloon luer fitting 26 and the x-ray tube 22 is turned on and energized.
- the radiosensitizer 19 is then released to the target region 34 by any of the means described above while the x-ray tube 22 is translated along an axial line through a center of the balloon 18 to direct an x-ray radiation dose to the target region 34 .
- the radiation and radiosensitizer delivery is carried out for a predetermined period of time calculated to deliver an effective dosage/concentration to the wall of the blood vessel to inhibit hyperplasia.
- radiation and radiosensitizer delivery may be carried out simultaneously or sequentially.
- the combination radiation and radiosensitizer delivery catheter 10 comprises a shaft or body 12 , a radioisotopic balloon 22 ′ coupleable to the catheter body 12 for applying a radiation dose to a target region 34 in a body lumen 32 , and a matrix 21 coupleable to the radioisotopic balloon 22 ′ for releasing a radiosensitizer 19 to the target region 34 .
- the radioisotopic balloon 22 ′ is an elastic or preferably an inelastic balloon, which may preferably be made from polyethylene terephthalate (PET), polyvinyl chloride (PVC), or other medical grade material suitable for constructing a strong non-compliant balloon.
- a shielded injector 38 which may be a manual or automated syringe containing a radioisotopic liquid 40 , or a pump connected to a reservoir of radioisotopic liquid 40 , is connected to the proximal end of shaft 12 .
- Shielded injector 38 is in fluid communication with a radioisotopic inflation lumen, which in turn is in fluid communication with radioisotopic balloon 22 ′ via radioisotopic inflation lumen ports.
- the shielded injector 38 is equipped with a fail-safe non-detachable connector 42 , which cannot be detached from the corresponding receptacle 44 of shaft 12 once it is attached thereto.
- Non-detachable connector 42 also prevents the radioisotopic fluid 40 from being discharged from injector 38 until the connector is connected to the receptacle in shaft 12 .
- Connectors having ring-detents and other non-detachable fluid fittings are well known in the art, as are piercing valves and other common methods of preventing fluid flow prior to attachment of a fluid fitting.
- the catheter 10 of FIG. 5 is advanced within the patient's blood vessel 32 by conventional means so that the radioisotopic balloon 22 ′ is positioned at a target region 34 .
- the radioisotopic balloon 22 ′ is then inflated with the liquid containing the radioisotope (via shielded injector 38 ) so it can direct a substantially uniform radiation dose while the matrix 21 allows for release of the radiosensitizer 19 to the target region 34 .
- the radioisotopic balloon 22 ′ is maintained in this inflated state for a predetermined period of time calculated to deliver an effective dosage/concentration of radiation and radiosensitizer to the wall of the blood vessel to inhibit hyperplasia.
- the combined radiation and radiosensitizer delivery catheter 10 for inhibiting hyperplasia comprises a catheter body 12 having an infusion port 46 for releasing a radiosensitizer, a pair of axially spaced apart balloons 18 ′ and 20 ′ on the catheter body 12 , and a radiation source 22 ′′.
- the infusion ports 46 are in fluid communication with the guidewire lumen.
- the radiation source 22 ′′ applies a radiation dose between the axially spaced apart balloons 18 ′ and 20 ′ while the infusion ports 46 directly infuse the radiosensitizer 19 therein, as shown in FIG. 8 .
- Balloons 18 ′ and 20 ′ comprise inelastic or preferably elastic balloons, which are preferably made of polyurethane, Pebax, or other medical grade elastomeric material suitable for constructing puncture-resistant elastic balloons.
- Balloons 18 ′ and 20 ′ are generally inflatable with a commonly used non-toxic radiopaque contrast medium. Suitable inflation media includes Hexabrix 320TM (sold commercially by Mallinkrodt Corp.) and IopamironTM (sold commercially by Schering-Plough Corp.). Contrast media with higher concentrations of the radiopaque material (e.g. iodine) are preferred.
- such a two balloon catheter embodiment be employed in the peripheral arteries as such a structure may help center and correctly position the radiation source 22 ′′ in the peripheral vessels, provide a pocket for drug delivery by the infusion ports 46 , and aid in uniform radiation dosimetry (which is described in more detail in co-pending U.S. patent application Ser. No. 9/653,444).
- the radiation source 22 ′′ depicted in FIG. 7 is a receptacle or lumen 22 ′′ in the catheter shaft 12 for receiving radioisotopic materials, like pellets or liquids, and delivering them through the catheter into the wall of a blood vessel.
- Receptacle 22 ′′ illustrates that the radiation source does not have to be an active source integrated into the catheter, but rather can be a receptacle 22 ′′ in the catheter for receiving radioisotopic material.
- the catheter will usually include a radioisotopic inflation lumen to permit introduction and removal of the radioisotopic materials to the receptacle 22 ′′.
- Radioisotopic materials may be selected to emit alpha, beta, or gamma radiation.
- the preferred liquid radioisotopic material will have relatively short half-lives. A shorter half-life is preferred because in the event of a catastrophic failure involving leakage of radioisotopic material into the patient's blood stream, for a given calculated dose, a shorter half life can result in a lesser total body dosage.
- Suitable emitters of low penetrating radiation for use according the present invention include 90 Strontium, 90 Yttrium, 32 Phosphorus, 125 Iodine, and 103 Palladium. These emitters may be incorporated into or delivered in a solid, liquid, or gaseous form.
- the catheter 10 of FIG. 7 is advanced within the patient's blood vessel 32 by conventional means so that the balloons 18 ′ and 20 ′ are each positioned on an end of a treatment region 34 to isolate the target region.
- Balloons 18 ′ and 20 ′ are then inflated (via the balloon luer fitting 26 ) in the blood vessel with non-toxic radiopaque contrast medium until the blood flow past the balloons is substantially stopped (the flow of blood in the vessel itself continues through the perfusion ports 28 ).
- Balloons 18 ′ and 20 ′ may also aid in centering the radiation source 22 ′′ within the blood vessel lumen as well as act as markers for proper positioning of the distal end 16 of catheter 10 within the treatment region 34 of the blood vessel under fluoroscopy.
- a radioisotope is then introduced into the receptacle 22 ′′ (via shielded injector 38 ) to the isolated target region to direct a substantially uniform radiation dose over an entire distance between the axially spaced apart balloons 18 ′ and 20 ′.
- the radiosensitizer 19 is also released between the first and second balloons 18 ′ and 20 ′ by the infusion ports 46 .
- Balloons 18 ′ and 20 ′ advantageously attenuate radiation from reaching tissue beyond the balloons so as to deliver an effective uniform dose of radiation to the wall of the blood vessel while providing an isolated region or pocket for drug 19 delivery.
- the radiation and radiosensitizer delivery is carried out for a predetermined period of time calculated to deliver an effective dosage/concentration to the wall of the blood vessel to inhibit hyperplasia.
- this schematic illustrates a kit 60 including a combination radiation and radiosensitizer delivery catheter 10 of FIG. 1 and its instructions for use 62 .
- the combination delivery catheter 10 may be replaced by any of the catheter structures described herein, while the instructions for use 62 will generally recite the steps for performing one or more of the above described methods.
- the instructions 62 will often be printed, optionally being at least in-part disposed on packaging.
- the instructions 62 may alternatively comprise a videotape, a CD-ROM or other machine readable code, a graphical representation, or the like showing any of the above described methods.
- the catheter of FIG. 1 may comprise a radioisotope radiation source or two microporous balloons for releasing the radiosensitizer.
- the delivery catheter and methods of the present invention may be part of a catheter that combines balloon angioplasty and/or other interventional treatments, like stent placement, with the presently claimed radiation and radiosensitizer delivery catheter.
Abstract
Description
- This application is a divisional of and claims the benefit of priority from U.S. patent application Ser. No. 09/851,372, filed May 7, 2001, the full disclosure of which is incorporated herein by reference.
- 1. Field of Invention
- The present invention relates generally to medical devices and methods for inhibiting restenosis in a blood vessel after an initial treatment for opening a stenotic region in a blood vessel. More particularly, the present invention relates to combination radiation and radiosensitizer delivery devices for inhibiting hyperplasia following balloon angioplasty and other interventional treatments.
- A number of percutaneous intravascular procedures have been developed for treating stenotic atherosclerotic regions of a patient's vasculature to restore adequate blood flow. The most successful of these treatments is percutaneous transluminal angioplasty (PTA). In PTA, a catheter, having an expansible distal end usually in the form of an inflatable balloon, is positioned in the blood vessel at the stenotic site. The expansible end is expanded to dilate the vessel to restore adequate blood flow beyond the diseased region. Other procedures for opening stenotic regions include directional atherectomy, rotational atherectomy, laser angioplasty, stenting, and the like. While these procedures have gained wide acceptance (either alone or in combination, particularly PTA in combination with stenting), they continue to suffer from significant disadvantages. A particularly common disadvantage with PTA and other known procedures for opening stenotic regions is the frequent occurrence of restenosis.
- Restenosis refers to the re-narrowing of an artery after an initially successful angioplasty. Restenosis afflicts approximately up to 50% of all angioplasty patients and is the result of injury to the blood vessel wall during the lumen opening angioplasty procedure. In some patients, the injury initiates a repair response that is characterized by smooth muscle cell proliferation referred to as “hyperplasia” in the region traumatized by the angioplasty. This proliferation of smooth muscle cells re-narrows the lumen that was opened by the angioplasty within a few weeks to a few months, thereby necessitating a repeat PTA or other procedure to alleviate the restenosis so that blood perfusion may be restored.
- A number of strategies have been proposed to treat hyperplasia and reduce restenosis. Previously proposed strategies include prolonged balloon inflation during angioplasty, treatment of the blood vessel with a heated balloon, stenting of the region, use of radiotherapy to treat in-stent restenosis, the administration of therapeutic drugs following angioplasty, and other procedures. While these proposals have enjoyed varying levels of success, no one of these procedures is proven to be entirely successful in completely avoiding all occurrences of restenosis and hyperplasia.
- As an alternative to the above mentioned therapies, the combination of radioisotope radiation and drug therapy following PTA for the inhibition of hyperplasia has also been proposed. Drug therapy infuses or releases a drug through a catheter or from a stent, while intravascular radiotherapy may configure catheters, guidewires, and stents to position a solid radioisotopic source (such as a wire, strip, pellet, seed, bead, or the like). While combination delivery of therapeutic agents with radioisotopic sources holds promise, optimum combinations of drugs and radiation have yet to be identified.
- For these reasons, it would be desirable to provide improved devices and methods for inhibiting restenosis and hyperplasia following angioplasty and other interventional treatments. In particular, it would be desirable to provide improved devices, methods, and kits for delivery of new and optimum drugs in combination with ionizing radiation to a blood vessel to reduce and/or inhibit restenosis and hyperplasia rates with increased efficacy. It would further be desirable to provide such devices and methods which significantly reduce dose concentrations of the drugs and/or radiation within the vessel wall while delivering sufficiently uniform radiation dosages and promoting endothelialization of the vessel wall. At least some of these objectives will be met by the devices and methods of the present invention described hereinafter.
- 2. Description of Background Art
- Full descriptions of exemplary x-ray sources for use in the present invention are described in co-pending U.S. patent application Ser. No. 09/299,304, assigned to the assignee herein, and U.S. Pat. No. 6,095,966, licensed to the assignee herein. Devices and methods for exposing intravascular and other treatment locations to radioisotopic materials in combination with therapeutic drugs are described in the following: U.S. Pat. Nos. 6,149,574; 5,993,374; 5,951,458; and International Publication Nos. WO 00/47197; WO 00/00238; WO 99/55285; WO 99/51299; WO 98/36790; and WO 96/23543. The use of texaphyrins for radiation sensitization is described in U.S. Pat. No. 6,072,038. Devices and methods for exposing intravascular locations to radioactive materials are described in the following: U.S. Pat. Nos. 6,069,938; 5,971,909; 5,653,736; 5,643,171; 5,624,372; 5,618,266; 5,616,114; 5,540,659; 5,505,613; 5,503,613; 5,498,227; 5,484,384; 5,411,466; 5,354,257; 5,302,168; 5,256,141; 5,213,561; 5,199,939; 5,061,267; and 5,059,166, European applications 860 180; 688 580; 633 041; and 593 136, and International Publications WO 97/07740; WO 96/14898; and WO 96/13303. Drug delivery within the vasculature is described in U.S. Pat. Nos. 6,099,561; 6,071,305; 6,063,101; 5,997,468; 5,980,551; 5,980,566; 5,972,027; 5,968,092; 5,951,586; 5,893,840; 5,891,108; 5,851,231; 5,843,172; 5,837,008; 5,769,883; 5,735,811; 5,700,286; 5,681,558; 5,679,400; 5,649,977; 5,637,113; 5,609,629; 5,591,227; 5,551,954; 5,545,208; 5,500,013; 5,464,450; 5,419,760; 5,411,550; 5,342,348; 5,286,254; and 5,163,952. Biodegradable materials are described in U.S. Pat. Nos. 5,876,452; 5,656,297; 5,543,158; 5,484,584; 4,897,268; 4,883,666; 4,832,686; and 3,976,071.
- The disclosure of this application is related to the disclosures of U.S. patent application Ser. No. 09/850,721 filed on May 7, 2001 (now U.S. Pat. No. 6,537,195) and U.S. patent application Ser. No. 09/850,728 also filed on May 7, 2001.
- The full disclosures of each of the above references are incorporated herein by reference.
- The present invention provides improved devices, methods, and kits for inhibiting restenosis and hyperplasia after intravascular intervention. In particular, the present invention provides controlled radiosensitizer delivery in combination with ionizing radiation delivery to selected locations within a patient's vasculature to reduce and/or inhibit restenosis and hyperplasia rates with increased efficacy. The methods and apparatus of the present invention can significantly reduce dose concentrations of radiosensitizers and/or radiation within the vessel wall while delivering sufficiently uniform radiation dosages and promoting endothelialization of the vessel wall.
- The term “intravascular intervention” includes a variety of corrective procedures that may be performed to at least partially resolve a stenotic condition. Usually, the corrective procedure will comprise balloon angioplasty. The corrective procedure could also comprise atherectomy, rotational atherectomy, laser angioplasty, stenting, or the like, where the lumen of the treated blood vessel is enlarged to at least partially alleviate a stenotic condition which existed prior to the treatment. The corrective procedure could also involve coronary artery bypass, vascular graft implantation, endarterectomy, or the like.
- By “controlled” radiosensitizer delivery, it is meant that a predetermined amount of the radiosensitizer is released or delivered at a predetermined rate to a blood vessel. Typically, such controlled delivery maintains a steady-state concentration of the radiosensitizer in a vascular environment within a desired therapeutic range of time, e.g. hours, days, weeks, or in some cases months.
- In a first aspect of the present invention, a combination radiation and radiosensitizer delivery catheter for inhibiting hyperplasia generally comprises a catheter body having a proximal end and distal end, a ionizing radiation source coupleable to the catheter body for applying a radiation dose to a body lumen, and means coupleable to the catheter body or the radiation source for releasing a radiosensitizer to the body lumen. The body lumen may be any blood vessel in the patient's vasculature, including veins, arteries, aorta, and particularly including peripheral and coronary arteries.
- The ionizing radiation source is preferably an x-ray tube since it provides many advantages, such as convenient dosing where the source may be easily turned on and off, minimal disposal problems, and the like. Alternatively, the ionizing radiation source may comprise a radioisotope, such as a solid radioisotopic source (e.g., wire, strip, pellet, seed, bead, or the like), or a liquid radioisotopic filled balloon. In the latter case, the balloon has been specially configured to prevent leakage of the radioisotopic material from the balloon into the body lumen or blood stream. Still further, the ionizing radiation source may comprise a receptacle in the catheter body for receiving radioisotopic materials like pellets or liquids. The radioisotopic material may be selected to emit alpha, beta, or gamma radiation. Usually, alpha and beta radiation are preferred since they may be quickly absorbed by surrounding tissue and will not penetrate substantially beyond the wall of the body lumen being treated. Accordingly, incidental irradiation of the heart and other organs adjacent to the treatment region can be substantially eliminated.
- The means may comprise a source of at least one radiosensitizer selected from the group consisting of taxol, nisonidazole, metronidazole, etanidazole, 5-fluorouracil, texaphyrin, C225 (an anti-EGFR monoclonal antibody), and cyclooxygenase-2 inhibitor. The radiosensitizer may also be a prodrug (e.g., precursor substances that are converted into an active form in the body) of any of the above described radiosensitizers. More preferably, the means comprises a source of taxol, incorporated in a solution with polyoxyethylated castor oil and dehydrated alcohol. The radiosensitizer may also be attached or encapsulated in a lipid or surfactant carrier.
- The combination of radiosensitizers and radiation therapy reduces and/or inhibits restenosis and hyperplasia rates with increased efficiency. In some instances, at least, it will be expected that the radiation will provide an immediate inhibition of cell proliferation while the radiosensitizers, which may be released over relatively long periods of time, e.g. days, weeks, or in some cases months, will provide prolonged inhibition. The delivery of radiosensitizers is particularly advantageous since radiosensitizers provide synergistic enhancement to radiation effects, such as enhancing apoptosis of proliferative smooth muscle cells and/or minimizing smooth muscle cell proliferation. In particular, radiosentizers may enhance the effect of radiation by increasing the cell cycle in which proliferative smooth muscle cells are most susceptible to radiation. Moreover, radiosentizers may inhibit radiation DNA damage repair of proliferative smooth muscle cells to further reduce and/or inhibit restenosis and hyperplasia. It will be appreciated that many of the above described radiosensitizers may also promote endothelialization of the vessel wall, which is needed for healing. Furthermore, a combined balance of both therapies allows for reduced dosages/concentrations of radiation and/or radiosensitizers in the body lumen, as compared to relying on a single therapy with an increased dosage which may not be as effective.
- It will be appreciated that there are a number of means available for releasing any of the above described radiosensitizers. Conventional intravascular delivery devices typically comprise a source of the radiosensitizer, that may be external or internal to the device, and means for controlled radiosensitizer release to the body lumen. Such means may comprise a porous material which contains the radiosensitizer, wherein the radiosensitizer may elute out at a controlled rate from the pores. Such means may alternatively comprise a matrix, membrane, barrier, or coating which includes the radiosensitizer. Usually, such a matrix comprises a rate controlling material wherein the rate controlling material controls the rate at which the radiosensitizer is released from the matrix. Such means may further comprise an infusion lumen for radiosensitizer release or a radiosensitizer eluting stent or graft. Still further, such means may comprise a reservoir containing the radiosensitizer and a cover over the reservoir. Typically, the cover comprises a matrix, membrane, or barrier which in turn controls the rate at which the radiosensitizer is released from the reservoir.
- In one embodiment, the means for releasing the radiosensitizer may comprise at least one microporous balloon on the catheter body. It is presently preferred that such a one balloon embodiment be employed in the coronary arteries as these vessels are relatively limited in size. The microporous balloon is usually inflated with any of the above described radiosensitizers and the radiosensitizer is released at a controlled rate from the microporous balloon by elution from pores. The microporous balloon is preferably elastic and made from nylon, Pebax, polyurethane, or like materials. The ionizing radiation source is typically positionable within the balloon.
- In another embodiment, the means for releasing the radiosensitizer may comprise a matrix, membrane, barrier, or coating formed over at least a portion of at least one balloon on the catheter body. The radiosensitizer may be disposed in the matrix or on a surface of the balloon beneath the matrix and the ionizing radiation source is typically positionable within the balloon. The matrix will typically comprise a rate controlling material, wherein the rate controlling material controls the rate at which the radiosensitizer is released from or through the matrix. The rate controlling material may be composed of degradable, partially degradable, nondegradable polymer, synthetic, or natural material. The matrix may degrade by bulk degradation, in which the matrix degrades throughout, or preferably by surface degradation, in which a surface of the matrix degrades over time while maintaining bulk integrity, to allow release of the radiosensitizer. Alternatively, a nondegradable matrix may release the radiosensitizer by diffusion through the matrix. Optionally, the rate controlling material may be porous so as to allow elution of the radiosensitizer from pores.
- In a further embodiment, the means may comprise a matrix, membrane, barrier, or coating formed over at least a portion of a radioisotopic balloon, wherein the radiosensitizer is in or beneath the matrix. The matrix may allow for controlled release of the radiosensitizer into the body lumen in a variety of forms as described above. Additionally, the liquid radioisotope filled balloon will serve as the ionizing radiation source.
- Any of the above described balloons may further comprise perfusion threading on an outer surface to allow for blood perfusion. Such threading may form a spiral, helical, or angled pattern on the balloon surface. The catheter of the present invention may alternatively be equipped with a perfusion lumen/port to permit blood flow past the balloon when inflated.
- In a second aspect of the present invention, a combined radiation and radiosensitizer delivery catheter for inhibiting hyperplasia generally comprises a catheter body having an infusion lumen for releasing a radiosensitizer, a pair of axially spaced apart balloons on the catheter body, and an ionizing radiation source. The ionizing radiation source applies a radiation dose between the axially spaced apart balloons while the infusion lumen releases the radiosensitizer therein. It is presently preferred that such a two balloon catheter embodiment be employed in the peripheral arteries as such a structure may help center and correctly position the radiation source in the peripheral vessels, provide a pocket for drug delivery, and aid in uniform radiation dosimetry, as described in greater detail in co-pending U.S. patent application Ser. No. 09/653,444, assigned the assignee herein, the full disclosure of which is incorporated herein by reference.
- In a third aspect of the present invention, methods for inhibiting hyperplasia in a body lumen are provided. One method includes releasing a radiosensitizer at a target region within the body lumen and directing ionizing radiation at the target region, wherein the radiosensitizer and radiation combine to inhibit hyperplasia. The “target region” will be a length within a blood vessel which is at risk of hyperplasia, typically as a result of the initial intravascular intervention(s). The method may further comprise inflating a balloon at the target region, wherein the radiosensitizer is released from the balloon. The balloon may be inflated with the radiosensitizer so that the radiosensitizer is released from an interior of the balloon through pores or the radiosensitizer may be released from a surface of the balloon through a rate controlling matrix. The method may optionally comprise isolating the target region, wherein the radiosensitizer is released into the isolated region. The isolating may comprises inflating a pair of axially spaced apart balloons or expanding a pair of axially spaced apart mechanical barriers. Typically, the ionizing radiation source is positioned within the balloon or the isolated target region. The ionizing radiation source may comprise an x-ray tube, wherein positioning generally comprises energizing the x-ray tube and translating the x-ray tube to traverse the target region. Alternatively, the ionizing radiation source may comprise a radioisotope or a receptacle in the catheter body. The ionizing radiation source generally applies a total radiation dose in a range from about 4 Gy to 24 Gy, preferably from 14 Gy to 20 Gy. The total amount of radiosensitizer released will typically depend on the specific radiosensitizer being delivered. The radiation dose and radiosensitizer release may additionally be carried out simultaneously or sequentially.
- In a fourth aspect of the present invention, kits comprising a catheter and instructions on how to use the catheter are provided. The kit may also include a source of the radiosensitizer. The catheter may comprise any of the delivery structures described herein, while the instructions for use will generally recite the steps for performing one or more of the above described methods. The instructions will often be printed, optionally being at least in-part disposed on packaging. The instructions may alternatively comprise a videotape, a CD-ROM or other machine readable code, a graphical representation, or the like showing any of the above described methods.
-
FIG. 1 is a plan view of an apparatus according the present invention. -
FIG. 2 is a cross sectional view of the apparatus ofFIG. 1 within a blood vessel. -
FIGS. 3A-3C illustrate various means for releasing a radiosensitizer. -
FIG. 4 illustrates a distal tip of the catheter ofFIG. 1 with a spiral perfusion balloon. -
FIG. 5 is a plan view of an alternate embodiment of an apparatus according to the present invention. -
FIG. 6 is a cross sectional view of the apparatus ofFIG. 5 within a blood vessel. -
FIG. 7 is a plan view of another alternate embodiment of an apparatus according to the present invention. -
FIG. 8 is a cross sectional view of the apparatusFIG. 7 within a blood vessel. -
FIG. 9 illustrates a combination radiation and radiosensitizer delivery kit including the apparatus ofFIG. 1 and instructions for its use. - The present invention provides improved devices, methods, and kits for inhibiting restenosis and hyperplasia after intravascular intervention. In particular, the present invention provides controlled radiosensitizer delivery in combination with ionizing radiation delivery to selected locations within a patient's vasculature to reduce and/or inhibit restenosis and hyperplasia rates with increased efficacy.
-
FIGS. 1 and 2 illustrate a combination radiation andradiosensitizer delivery catheter 10 constructed in accordance with the principles of the present invention. The combination radiation andradiosensitizer delivery catheter 10 comprises a shaft orbody 12 having aproximal end 14 anddistal end 16, aradiation source 22 coupleable to thedistal end 16 of thecatheter body 12 for applying a radiation dose to atarget region 34 in abody lumen 32, and means coupleable to thedistal end 16 of thecatheter body 12 for releasing aradiosensitizer 19 to thetarget region 34. Theproximal end 14 ofshaft 12 includes a guidewire lumen luer fitting 24 and a balloon luer fitting 26. The guidewire luer fitting 24 is in fluid communication with a guidewire/perfusion lumen that is in turn in fluid communication withperfusion ports 28.Perfusion ports 28 are well known in the art as a means of permitting some blood flow past aballoon 18 that is inflated or otherwise blocking a blood vessel. The balloon luer fitting 26 is in fluid communication with a balloon inflation lumen that is in turn in fluid communication withballoon 18. It will be appreciated that the following depictions are for illustration purposes only and does not necessarily reflect the actual shape, size, or distribution of thedelivery catheter 10. - The
body lumen 32 may be any blood vessel in the patient's vasculature, including veins, arteries, aorta, and particularly including peripheral and coronary arteries. It will be appreciated that the present invention may also find use inbody lumens 32 other than blood vessels. For example, the present invention may be applied to many internal corporeal tissue organs, such as organs, nerves, glands, ducts, and the like. - The
radiation source 22 may be a radioisotope or a receptacle for receiving radioisotopic materials. Radioisotope sources may comprise a point source, wire, strip, pellet, seed, bead, liquid radioisotope balloon, and the like, selected to emit alpha, beta, or gamma radiation. In an exemplary embodiment, theradiation source 22 is an x-ray tube, as illustrated inFIGS. 1 and 2 . Thex-ray tube 22 can be isotropic, such as a transmission anode, or non-isotropic, such as an opaque anode. The x-ray will typically operate at an energy in the range from 18 kV to 28 kV. Exemplary x-ray sources are described in co-pending application Ser. No. 09/299,304, assigned to the assignee herein, and U.S. Pat. No. 6,095,966, licensed to the assignee herein. Other suitable x-ray sources are described in U.S. Pat. Nos. 6,134,300 and 5,428,658, and U.S. Reissue 34,421, the full disclosures of which are incorporated herein by reference. The total amount of radiation applied depends in part on the level and amount of vessel injury, as well as the total amount of radiosensitizer delivered, and will typically be in a range from about 4 Gy to 24 Gy, preferably from 14 Gy to 24 Gy. As described above, anx-ray tube 22 is preferable as it provides many advantages, such as, convenient dosing where the source may be easily turned on and off, eliminates the need to prepare, handle, and dispose of radioisotopes, and the like. -
Suitable radiosensitizers 19 include taxol, misonidazole, metronidazole, etanidazole, 5-fluorouracil, texaphyrin (e.g., Xcytrin™ sold commercially by Pharmacyclics, and RSR13™ sold commercially by Allos Therapeutics), C225, and cyclooxygenase-2 inhibitor. Theradiosensitizer 19 may also be a prodrug of any of the above described radiosensitizers. Preferably, theradiosensitizer 19 comprises taxol, alone or in combination with any of the other radiosensitizers described above. The total amount of radiosensitizer released depends on the specific radiosensitizer being delivered as well as on the level and amount of vessel injury and the total amount of radiation applied. For example, taxol may be released at levels of 130 micrograms/cm3 or less. - The combination of
radiosensitizers 19 andradiation 22 reduces and/or inhibits restenosis and hyperplasia rates with increased efficiency. The delivery ofradiosensitizers 19 is particularly advantageous since radiosensitizers provide synergistic enhancement to radiation effects, such as enhancing apoptosis of proliferative smooth muscle cells and/or minimizing smooth muscle cell proliferation. It will be appreciated that many of the above describedradiosensitizers 19 may also promote endothelialization of the vessel wall, which is needed for healing. Moreover, a combined balance of both therapies allows for reduced dosages/concentrations of radiation and/or radiosensitizers in the body lumen, as compared to relying on a single therapy with an increased dosage. - Referring now to
FIGS. 2 and 3 A, the means for releasing the radiosensitizer may comprise at least onemicroporous balloon 18 on thecatheter body 12. It is presently preferred that such a one balloon embodiment be employed in the coronary arteries. Themicroporous balloon 18 is usually inflated with any of the above describedradiosensitizers 19 via the balloon luer fitting 26. Theradiosensitizer 19 is then released from themicroporous balloon 18 by elution from pores. Themicroporous balloon 18 is preferably elastic and made from nylon, Pebax, polyurethane, or like materials, and may be an integral extension of thecatheter body 12, or attached to thedistal end 16 of thecatheter body 12 by suitable adhesives, heat welding, or the like. Thecatheter body 12 may be formed from conventional materials, such as polyethylenes, polyimides, and copolymers and derivatives thereof - Referring now to
FIGS. 3B and 3C , alternative means for releasing the radiosensitizer may comprise amatrix 21 formed over at least a portion of aballoon 18′ on thecatheter body 12. Thematrix 21 will typically comprise a rate controlling material, wherein the rate controlling material controls the rate at which theradiosensitizer 19 is released from or through thematrix 21. Theradiosensitizer 19 may be disposed on a surface of theballoon 18′, as illustrated inFIG. 3B , or within thematrix 21, as illustrated inFIG. 3C . Theballoon 18′ may be inelastic or preferably elastic, and is preferably made of polyurethane, Pebax, or other medical grade elastomeric material suitable for constructing puncture-resistant elastic balloons.Balloon 18′ is generally inflatable via the balloon luer fitting 26. The rate controlling material may comprise degradable, partially degradable, nondegradable polymer, synthetic, or natural material. The matrix may degrade by bulk degradation, in which the matrix degrades throughout, or preferably by surface degradation, in which a surface of the matrix degrades over time while maintaining bulk integrity, to allow release of the radiosensitizer. Alternatively, a nondegradable matrix may release the radiosensitizer by diffusion through the matrix. Optionally, the rate controlling material may be porous so as to allow elution of the radiosensitizer from pores. Typically, theradiosensitizer 19 and/or thematrix 21 are coated, sprayed, dipped, deposited, or painted on the balloon surface. - Referring now to
FIG. 4 , in some instances, any of the above described balloons may further incorporate a perfusion threading orband 36 affixed to an outer surface of theballoon 18 by adhesion bonding, heat welding, fasteners, or the like. Threading patterns may be spiral (as shown inFIG. 4 ), helical, or angled. The threading 36 may be formed from polymer materials and may aid in perfusion so as to permit blood flow past the balloon when inflated. - In operation, an appropriately
sized catheter 10 as illustrated inFIGS. 1 and 2 is advanced via aguidewire 30 within ablood vessel segment 32 having atreatment region 34 so that the radiation source 22 (which is positionable within the balloon 18) and the at least oneballoon 18 are positioned at thetarget region 32. Thetreatment region 34 has previously been enlarged by balloon angioplasty or other procedures such that atherosclerotic plaque has been radially compressed by expansion of the balloon portion of an angioplasty device (not shown). The balloon 18 (as shown inFIG. 2 ) is inflated in the blood vessel via the balloon luer fitting 26 and thex-ray tube 22 is turned on and energized. Theradiosensitizer 19 is then released to thetarget region 34 by any of the means described above while thex-ray tube 22 is translated along an axial line through a center of theballoon 18 to direct an x-ray radiation dose to thetarget region 34. The radiation and radiosensitizer delivery is carried out for a predetermined period of time calculated to deliver an effective dosage/concentration to the wall of the blood vessel to inhibit hyperplasia. Moreover, radiation and radiosensitizer delivery may be carried out simultaneously or sequentially. - Referring now to
FIGS. 5 and 6 , an alternative embodiment of an apparatus according to the present invention is illustrated. The combination radiation andradiosensitizer delivery catheter 10 comprises a shaft orbody 12, aradioisotopic balloon 22′ coupleable to thecatheter body 12 for applying a radiation dose to atarget region 34 in abody lumen 32, and amatrix 21 coupleable to theradioisotopic balloon 22′ for releasing aradiosensitizer 19 to thetarget region 34. Theradioisotopic balloon 22′ is an elastic or preferably an inelastic balloon, which may preferably be made from polyethylene terephthalate (PET), polyvinyl chloride (PVC), or other medical grade material suitable for constructing a strong non-compliant balloon. - A shielded
injector 38, which may be a manual or automated syringe containing a radioisotopic liquid 40, or a pump connected to a reservoir of radioisotopic liquid 40, is connected to the proximal end ofshaft 12. Shieldedinjector 38 is in fluid communication with a radioisotopic inflation lumen, which in turn is in fluid communication withradioisotopic balloon 22′ via radioisotopic inflation lumen ports. To prevent possible spillage and corresponding radioisotopic contamination of the operating room and/or its personnel, the shieldedinjector 38 is equipped with a fail-safenon-detachable connector 42, which cannot be detached from the correspondingreceptacle 44 ofshaft 12 once it is attached thereto.Non-detachable connector 42 also prevents the radioisotopic fluid 40 from being discharged frominjector 38 until the connector is connected to the receptacle inshaft 12. Connectors having ring-detents and other non-detachable fluid fittings are well known in the art, as are piercing valves and other common methods of preventing fluid flow prior to attachment of a fluid fitting. - In operation, after intravascular intervention, the
catheter 10 ofFIG. 5 is advanced within the patient'sblood vessel 32 by conventional means so that theradioisotopic balloon 22′ is positioned at atarget region 34. Theradioisotopic balloon 22′ is then inflated with the liquid containing the radioisotope (via shielded injector 38) so it can direct a substantially uniform radiation dose while thematrix 21 allows for release of theradiosensitizer 19 to thetarget region 34. Theradioisotopic balloon 22′ is maintained in this inflated state for a predetermined period of time calculated to deliver an effective dosage/concentration of radiation and radiosensitizer to the wall of the blood vessel to inhibit hyperplasia. - Referring now to
FIGS. 7 and 8 , an additional embodiment of the present invention is illustrated. The combined radiation andradiosensitizer delivery catheter 10 for inhibiting hyperplasia comprises acatheter body 12 having aninfusion port 46 for releasing a radiosensitizer, a pair of axially spaced apart balloons 18′ and 20′ on thecatheter body 12, and aradiation source 22″. Theinfusion ports 46 are in fluid communication with the guidewire lumen. Theradiation source 22″ applies a radiation dose between the axially spaced apart balloons 18′ and 20′ while theinfusion ports 46 directly infuse theradiosensitizer 19 therein, as shown inFIG. 8 . -
Balloons 18′ and 20′ comprise inelastic or preferably elastic balloons, which are preferably made of polyurethane, Pebax, or other medical grade elastomeric material suitable for constructing puncture-resistant elastic balloons.Balloons 18′ and 20′ are generally inflatable with a commonly used non-toxic radiopaque contrast medium. Suitable inflation media includes Hexabrix 320™ (sold commercially by Mallinkrodt Corp.) and Iopamiron™ (sold commercially by Schering-Plough Corp.). Contrast media with higher concentrations of the radiopaque material (e.g. iodine) are preferred. It is presently preferred that such a two balloon catheter embodiment be employed in the peripheral arteries as such a structure may help center and correctly position theradiation source 22″ in the peripheral vessels, provide a pocket for drug delivery by theinfusion ports 46, and aid in uniform radiation dosimetry (which is described in more detail in co-pending U.S. patent application Ser. No. 9/653,444). - The
radiation source 22″ depicted inFIG. 7 is a receptacle orlumen 22″ in thecatheter shaft 12 for receiving radioisotopic materials, like pellets or liquids, and delivering them through the catheter into the wall of a blood vessel.Receptacle 22″ illustrates that the radiation source does not have to be an active source integrated into the catheter, but rather can be areceptacle 22″ in the catheter for receiving radioisotopic material. The catheter will usually include a radioisotopic inflation lumen to permit introduction and removal of the radioisotopic materials to thereceptacle 22″. - Several important considerations must be balanced in the design of an apparatus for safely and effectively injecting a radioisotopic material into a patient to irradiate a blood vessel to prevent hyperplasia. Radioisotopic materials may be selected to emit alpha, beta, or gamma radiation. The preferred liquid radioisotopic material will have relatively short half-lives. A shorter half-life is preferred because in the event of a catastrophic failure involving leakage of radioisotopic material into the patient's blood stream, for a given calculated dose, a shorter half life can result in a lesser total body dosage. Radioisotopic material will be selected to provide a total radiation dose in the range from 4 Gray (Gy; 1 Gy=100 rads) to 24 Gy. Suitable emitters of low penetrating radiation for use according the present invention include 90 Strontium, 90 Yttrium, 32 Phosphorus, 125 Iodine, and 103 Palladium. These emitters may be incorporated into or delivered in a solid, liquid, or gaseous form.
- In operation, after intravascular intervention, the
catheter 10 ofFIG. 7 is advanced within the patient'sblood vessel 32 by conventional means so that theballoons 18′ and 20′ are each positioned on an end of atreatment region 34 to isolate the target region.Balloons 18′ and 20′ are then inflated (via the balloon luer fitting 26) in the blood vessel with non-toxic radiopaque contrast medium until the blood flow past the balloons is substantially stopped (the flow of blood in the vessel itself continues through the perfusion ports 28).Balloons 18′ and 20′ may also aid in centering theradiation source 22″ within the blood vessel lumen as well as act as markers for proper positioning of thedistal end 16 ofcatheter 10 within thetreatment region 34 of the blood vessel under fluoroscopy. A radioisotope is then introduced into thereceptacle 22″ (via shielded injector 38) to the isolated target region to direct a substantially uniform radiation dose over an entire distance between the axially spaced apart balloons 18′ and 20′. Theradiosensitizer 19 is also released between the first andsecond balloons 18′ and 20′ by theinfusion ports 46.Balloons 18′ and 20′ advantageously attenuate radiation from reaching tissue beyond the balloons so as to deliver an effective uniform dose of radiation to the wall of the blood vessel while providing an isolated region or pocket fordrug 19 delivery. The radiation and radiosensitizer delivery is carried out for a predetermined period of time calculated to deliver an effective dosage/concentration to the wall of the blood vessel to inhibit hyperplasia. - Referring now to
FIG. 9 , this schematic illustrates akit 60 including a combination radiation andradiosensitizer delivery catheter 10 ofFIG. 1 and its instructions foruse 62. Thecombination delivery catheter 10 may be replaced by any of the catheter structures described herein, while the instructions foruse 62 will generally recite the steps for performing one or more of the above described methods. Theinstructions 62 will often be printed, optionally being at least in-part disposed on packaging. Theinstructions 62 may alternatively comprise a videotape, a CD-ROM or other machine readable code, a graphical representation, or the like showing any of the above described methods. - In general, it will be possible to combine the elements of the differing catheters and treatment methods described above. For example, the catheter of
FIG. 1 may comprise a radioisotope radiation source or two microporous balloons for releasing the radiosensitizer. Additionally, the delivery catheter and methods of the present invention may be part of a catheter that combines balloon angioplasty and/or other interventional treatments, like stent placement, with the presently claimed radiation and radiosensitizer delivery catheter. - Although certain preferred embodiments and methods have been disclosed herein, it will be apparent from the foregoing disclosure to those skilled in the art that variations and modifications of such embodiments and methods may be made without departing from the true spirit and scope of the invention. Therefore, the above description should not be taken as limiting the scope of the invention which is defined by the appended claims.
Claims (21)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/009,501 US20050124844A1 (en) | 2001-05-07 | 2004-12-10 | Combination ionizing radiation and radiosensitizer delivery devices and methods for inhibiting hyperplasia |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/851,372 US7018371B2 (en) | 2001-05-07 | 2001-05-07 | Combination ionizing radiation and radiosensitizer delivery devices and methods for inhibiting hyperplasia |
US09/850,728 US7041046B2 (en) | 2001-05-07 | 2001-05-07 | Combination ionizing radiation and immunomodulator delivery devices and methods for inhibiting hyperplasia |
US11/009,501 US20050124844A1 (en) | 2001-05-07 | 2004-12-10 | Combination ionizing radiation and radiosensitizer delivery devices and methods for inhibiting hyperplasia |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/851,372 Division US7018371B2 (en) | 2001-05-07 | 2001-05-07 | Combination ionizing radiation and radiosensitizer delivery devices and methods for inhibiting hyperplasia |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050124844A1 true US20050124844A1 (en) | 2005-06-09 |
Family
ID=27126949
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/851,372 Expired - Fee Related US7018371B2 (en) | 2001-05-07 | 2001-05-07 | Combination ionizing radiation and radiosensitizer delivery devices and methods for inhibiting hyperplasia |
US09/850,728 Expired - Lifetime US7041046B2 (en) | 2001-05-07 | 2001-05-07 | Combination ionizing radiation and immunomodulator delivery devices and methods for inhibiting hyperplasia |
US11/009,501 Abandoned US20050124844A1 (en) | 2001-05-07 | 2004-12-10 | Combination ionizing radiation and radiosensitizer delivery devices and methods for inhibiting hyperplasia |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/851,372 Expired - Fee Related US7018371B2 (en) | 2001-05-07 | 2001-05-07 | Combination ionizing radiation and radiosensitizer delivery devices and methods for inhibiting hyperplasia |
US09/850,728 Expired - Lifetime US7041046B2 (en) | 2001-05-07 | 2001-05-07 | Combination ionizing radiation and immunomodulator delivery devices and methods for inhibiting hyperplasia |
Country Status (2)
Country | Link |
---|---|
US (3) | US7018371B2 (en) |
WO (1) | WO2002089899A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080009658A1 (en) * | 2006-06-19 | 2008-01-10 | Smith Peter C | Radiation therapy apparatus with selective shielding capability |
US20100280374A1 (en) * | 2007-09-19 | 2010-11-04 | Roberts Walter A | Direct Visualization Robotic Intra-Operative Radiation Therapy Applicator Device |
US8663210B2 (en) | 2009-05-13 | 2014-03-04 | Novian Health, Inc. | Methods and apparatus for performing interstitial laser therapy and interstitial brachytherapy |
US20140094777A1 (en) * | 2011-10-03 | 2014-04-03 | Gwendolyn Watanabe | Dual purpose balloon catheters |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1461122A4 (en) * | 2001-12-10 | 2006-08-23 | Control Delivery Sys Inc | Treatment of genitourinary tract disorders |
US7018346B2 (en) | 2001-12-18 | 2006-03-28 | Scimed Life Systems, Inc. | Guide wire with adjustable flexibility |
US6884342B2 (en) * | 2002-02-28 | 2005-04-26 | Bioprocess Technologies Ltd. | Wastewater trickle tower biomedia strands arrangement |
US7378048B2 (en) * | 2002-12-03 | 2008-05-27 | Boston Scientific Scimed, Inc. | Method for forming catheter curves |
WO2005009480A2 (en) * | 2003-06-11 | 2005-02-03 | Control Delivery Systems, Inc. | Implants containing codrugs |
US20050015049A1 (en) * | 2003-07-16 | 2005-01-20 | Rioux Robert F. | Temporary tissue spacer and pretreatment balloon |
US7524275B2 (en) * | 2003-11-14 | 2009-04-28 | Cytyc Corporation | Drug eluting brachytherapy methods and apparatus |
EP2298412A1 (en) * | 2004-02-12 | 2011-03-23 | Neovista, Inc. | Apparatus for intraocular brachytherapy |
US20060063973A1 (en) | 2004-04-21 | 2006-03-23 | Acclarent, Inc. | Methods and apparatus for treating disorders of the ear, nose and throat |
US8894614B2 (en) | 2004-04-21 | 2014-11-25 | Acclarent, Inc. | Devices, systems and methods useable for treating frontal sinusitis |
US9351750B2 (en) | 2004-04-21 | 2016-05-31 | Acclarent, Inc. | Devices and methods for treating maxillary sinus disease |
US10188413B1 (en) | 2004-04-21 | 2019-01-29 | Acclarent, Inc. | Deflectable guide catheters and related methods |
US8932276B1 (en) | 2004-04-21 | 2015-01-13 | Acclarent, Inc. | Shapeable guide catheters and related methods |
US9089258B2 (en) | 2004-04-21 | 2015-07-28 | Acclarent, Inc. | Endoscopic methods and devices for transnasal procedures |
US9399121B2 (en) | 2004-04-21 | 2016-07-26 | Acclarent, Inc. | Systems and methods for transnasal dilation of passageways in the ear, nose or throat |
US7462175B2 (en) | 2004-04-21 | 2008-12-09 | Acclarent, Inc. | Devices, systems and methods for treating disorders of the ear, nose and throat |
US8702626B1 (en) | 2004-04-21 | 2014-04-22 | Acclarent, Inc. | Guidewires for performing image guided procedures |
US20070167682A1 (en) | 2004-04-21 | 2007-07-19 | Acclarent, Inc. | Endoscopic methods and devices for transnasal procedures |
US7559925B2 (en) | 2006-09-15 | 2009-07-14 | Acclarent Inc. | Methods and devices for facilitating visualization in a surgical environment |
US8764729B2 (en) | 2004-04-21 | 2014-07-01 | Acclarent, Inc. | Frontal sinus spacer |
US7419497B2 (en) | 2004-04-21 | 2008-09-02 | Acclarent, Inc. | Methods for treating ethmoid disease |
US8864787B2 (en) | 2004-04-21 | 2014-10-21 | Acclarent, Inc. | Ethmoidotomy system and implantable spacer devices having therapeutic substance delivery capability for treatment of paranasal sinusitis |
US20190314620A1 (en) | 2004-04-21 | 2019-10-17 | Acclarent, Inc. | Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures |
US9554691B2 (en) | 2004-04-21 | 2017-01-31 | Acclarent, Inc. | Endoscopic methods and devices for transnasal procedures |
US7803150B2 (en) | 2004-04-21 | 2010-09-28 | Acclarent, Inc. | Devices, systems and methods useable for treating sinusitis |
US8747389B2 (en) | 2004-04-21 | 2014-06-10 | Acclarent, Inc. | Systems for treating disorders of the ear, nose and throat |
US9101384B2 (en) | 2004-04-21 | 2015-08-11 | Acclarent, Inc. | Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, Nose and/or throat |
US7654997B2 (en) | 2004-04-21 | 2010-02-02 | Acclarent, Inc. | Devices, systems and methods for diagnosing and treating sinusitus and other disorders of the ears, nose and/or throat |
US20070208252A1 (en) | 2004-04-21 | 2007-09-06 | Acclarent, Inc. | Systems and methods for performing image guided procedures within the ear, nose, throat and paranasal sinuses |
US7828790B2 (en) | 2004-12-03 | 2010-11-09 | Boston Scientific Scimed, Inc. | Selectively flexible catheter and method of use |
EP2535079A3 (en) * | 2005-01-18 | 2013-02-13 | Acclarent, Inc. | Paranasal sinus lavage device |
US8951225B2 (en) | 2005-06-10 | 2015-02-10 | Acclarent, Inc. | Catheters with non-removable guide members useable for treatment of sinusitis |
EP1951372A4 (en) * | 2005-11-15 | 2011-06-22 | Neovista Inc | Methods and apparatus for intraocular brachytherapy |
US9820688B2 (en) | 2006-09-15 | 2017-11-21 | Acclarent, Inc. | Sinus illumination lightwire device |
KR20120106880A (en) | 2007-01-21 | 2012-09-26 | 헤모텍 아게 | Medical product for treating stenosis of body passages and for preventing threatening restenosis |
US9192697B2 (en) | 2007-07-03 | 2015-11-24 | Hemoteq Ag | Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis |
EP2195091B1 (en) * | 2007-08-29 | 2011-06-22 | Acrostak Corp. | Kit for delivery of brachytherapy to a subject |
US20090209803A1 (en) * | 2008-02-14 | 2009-08-20 | Lovoi Paul A | Adjuvant brachytherapy apparatus and method for use with kyphoplasty |
US8206430B2 (en) * | 2008-04-21 | 2012-06-26 | Medtronic Vascular, Inc. | Endolumenal sealant delivery apparatus and methods |
US20090270787A1 (en) * | 2008-04-23 | 2009-10-29 | Abbott Cardiovascular Systems Inc. | Systems and methods for creating enlarged migration channels for therapeutic agents within the endothelium |
AU2009293312B2 (en) | 2008-09-18 | 2015-07-09 | Acclarent, Inc. | Methods and apparatus for treating disorders of the ear nose and throat |
CA2743491C (en) | 2008-11-11 | 2016-10-11 | Zelton Dave Sharp | Inhibition of mammalian target of rapamycin |
WO2011005421A2 (en) | 2009-07-10 | 2011-01-13 | Boston Scientific Scimed, Inc. | Use of nanocrystals for a drug delivery balloon |
EP2453938B1 (en) | 2009-07-17 | 2015-08-19 | Boston Scientific Scimed, Inc. | Nucleation of drug delivery balloons to provide improved crystal size and density |
US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
US10391059B2 (en) | 2009-11-11 | 2019-08-27 | Rapamycin Holdings, Inc. | Oral rapamycin nanoparticle preparations and use |
DE102010019422B4 (en) * | 2010-05-05 | 2013-05-16 | ITM Isotopen Technologien München AG | Positioning catheter for intravascular irradiation of coronary and peripheral vessels with radioactive rays |
WO2012031236A1 (en) | 2010-09-02 | 2012-03-08 | Boston Scientific Scimed, Inc. | Coating process for drug delivery balloons using heat-induced rewrap memory |
US9155492B2 (en) | 2010-09-24 | 2015-10-13 | Acclarent, Inc. | Sinus illumination lightwire device |
US8669360B2 (en) | 2011-08-05 | 2014-03-11 | Boston Scientific Scimed, Inc. | Methods of converting amorphous drug substance into crystalline form |
WO2013028208A1 (en) | 2011-08-25 | 2013-02-28 | Boston Scientific Scimed, Inc. | Medical device with crystalline drug coating |
ITMI20121183A1 (en) * | 2012-07-05 | 2014-01-06 | Ngc Medical S P A | DEVICE FOR THE TREATMENT OF A BLOOD VASE |
DK2968281T3 (en) | 2013-03-13 | 2020-11-02 | Univ Texas | MTOR INHIBITORS FOR PREVENTING THE GROWTH OF THE INTESTINAL POLYPH |
US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
WO2017205456A1 (en) | 2016-05-26 | 2017-11-30 | Merit Medical Systems, Inc. | Expandable introducer assembly |
EP3573699B1 (en) | 2017-01-27 | 2022-08-10 | Merit Medical Systems, Inc. | Disinfecting luer cap and method of use |
Citations (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US34421A (en) * | 1862-02-18 | Improvement in channeling-tools for harness-makers | ||
US3976071A (en) * | 1974-01-07 | 1976-08-24 | Dynatech Corporation | Methods of improving control of release rates and products useful in same |
US4636195A (en) * | 1982-04-02 | 1987-01-13 | Harvey Wolinsky | Method and apparatus for removing arterial constriction |
US4832686A (en) * | 1986-06-24 | 1989-05-23 | Anderson Mark E | Method for administering interleukin-2 |
US4883666A (en) * | 1987-04-29 | 1989-11-28 | Massachusetts Institute Of Technology | Controlled drug delivery system for treatment of neural disorders |
US4897268A (en) * | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
US5059166A (en) * | 1989-12-11 | 1991-10-22 | Medical Innovative Technologies R & D Limited Partnership | Intra-arterial stent with the capability to inhibit intimal hyperplasia |
US5061267A (en) * | 1987-12-22 | 1991-10-29 | Andreas Zeiher | Balloon catheter for rechanneling stenoses in body passages, in particular of coronary and peripheral arterial vessels |
US5090043A (en) * | 1990-11-21 | 1992-02-18 | Parker Micro-Tubes, Inc. | X-ray micro-tube and method of use in radiation oncology |
US5163952A (en) * | 1990-09-14 | 1992-11-17 | Michael Froix | Expandable polymeric stent with memory and delivery apparatus and method |
US5188595A (en) * | 1991-06-28 | 1993-02-23 | Laserscope | Method for enhanced retention of balloon catheter in body cavity |
US5199939A (en) * | 1990-02-23 | 1993-04-06 | Dake Michael D | Radioactive catheter |
US5213561A (en) * | 1990-09-06 | 1993-05-25 | Weinstein Joseph S | Method and devices for preventing restenosis after angioplasty |
US5256141A (en) * | 1992-12-22 | 1993-10-26 | Nelson Gencheff | Biological material deployment method and apparatus |
US5282785A (en) * | 1990-06-15 | 1994-02-01 | Cortrak Medical, Inc. | Drug delivery apparatus and method |
US5302168A (en) * | 1991-09-05 | 1994-04-12 | Hess Robert L | Method and apparatus for restenosis treatment |
US5318531A (en) * | 1991-06-11 | 1994-06-07 | Cordis Corporation | Infusion balloon catheter |
US5342348A (en) * | 1992-12-04 | 1994-08-30 | Kaplan Aaron V | Method and device for treating and enlarging body lumens |
US5354257A (en) * | 1991-01-29 | 1994-10-11 | Med Institute, Inc. | Minimally invasive medical device for providing a radiation treatment |
US5411550A (en) * | 1991-09-16 | 1995-05-02 | Atrium Medical Corporation | Implantable prosthetic device for the delivery of a bioactive material |
US5419760A (en) * | 1993-01-08 | 1995-05-30 | Pdt Systems, Inc. | Medicament dispensing stent for prevention of restenosis of a blood vessel |
US5464450A (en) * | 1991-10-04 | 1995-11-07 | Scimed Lifesystems Inc. | Biodegradable drug delivery vascular stent |
US5484384A (en) * | 1991-01-29 | 1996-01-16 | Med Institute, Inc. | Minimally invasive medical device for providing a radiation treatment |
US5484584A (en) * | 1990-10-02 | 1996-01-16 | Board Of Regents, The University Of Texas System | Therapeutic and diagnostic use of modified polymeric microcapsules |
US5498227A (en) * | 1993-09-15 | 1996-03-12 | Mawad; Michel E. | Retrievable, shielded radiotherapy implant |
US5500013A (en) * | 1991-10-04 | 1996-03-19 | Scimed Life Systems, Inc. | Biodegradable drug delivery vascular stent |
US5503613A (en) * | 1994-01-21 | 1996-04-02 | The Trustees Of Columbia University In The City Of New York | Apparatus and method to reduce restenosis after arterial intervention |
US5540659A (en) * | 1993-07-15 | 1996-07-30 | Teirstein; Paul S. | Irradiation catheter and method of use |
US5543158A (en) * | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
US5545208A (en) * | 1990-02-28 | 1996-08-13 | Medtronic, Inc. | Intralumenal drug eluting prosthesis |
US5551954A (en) * | 1991-10-04 | 1996-09-03 | Scimed Life Systems, Inc. | Biodegradable drug delivery vascular stent |
US5566221A (en) * | 1994-07-12 | 1996-10-15 | Photoelectron Corporation | Apparatus for applying a predetermined x-radiation flux to an interior surface of a body cavity |
US5569198A (en) * | 1995-01-23 | 1996-10-29 | Cortrak Medical Inc. | Microporous catheter |
US5591227A (en) * | 1992-03-19 | 1997-01-07 | Medtronic, Inc. | Drug eluting stent |
US5609629A (en) * | 1995-06-07 | 1997-03-11 | Med Institute, Inc. | Coated implantable medical device |
US5616114A (en) * | 1994-12-08 | 1997-04-01 | Neocardia, Llc. | Intravascular radiotherapy employing a liquid-suspended source |
US5618266A (en) * | 1994-03-31 | 1997-04-08 | Liprie; Samuel F. | Catheter for maneuvering radioactive source wire to site of treatment |
US5624372A (en) * | 1990-10-25 | 1997-04-29 | Omnitron International, Inc. | Source wire for localized internal irradiation of tissue |
US5637113A (en) * | 1994-12-13 | 1997-06-10 | Advanced Cardiovascular Systems, Inc. | Polymer film for wrapping a stent structure |
US5643171A (en) * | 1993-05-04 | 1997-07-01 | Neocardia, Llc | Method and apparatus for uniform radiation treatment of vascular lumens |
US5649977A (en) * | 1994-09-22 | 1997-07-22 | Advanced Cardiovascular Systems, Inc. | Metal reinforced polymer stent |
US5653736A (en) * | 1995-01-19 | 1997-08-05 | Cordis Corporation | Carrier balloon for a stent assembly with radiation-shielding capabilities |
US5656297A (en) * | 1992-03-12 | 1997-08-12 | Alkermes Controlled Therapeutics, Incorporated | Modulated release from biocompatible polymers |
US5679400A (en) * | 1993-04-26 | 1997-10-21 | Medtronic, Inc. | Intravascular stent and method |
US5681558A (en) * | 1995-11-30 | 1997-10-28 | Berlex Laboratories, Inc. | Method of using beta-interferons to treat restenosis |
US5704908A (en) * | 1996-10-10 | 1998-01-06 | Genetronics, Inc. | Electroporation and iontophoresis catheter with porous balloon |
US5735711A (en) * | 1993-08-27 | 1998-04-07 | Raychem Gmbh | Cable connector |
US5772642A (en) * | 1997-02-19 | 1998-06-30 | Medtronic, Inc. | Closed end catheter |
US5843172A (en) * | 1997-04-15 | 1998-12-01 | Advanced Cardiovascular Systems, Inc. | Porous medicated stent |
US5851231A (en) * | 1990-02-28 | 1998-12-22 | Medtronic, Inc. | Intralumenal drug eluting prosthesis |
US5863285A (en) * | 1997-01-30 | 1999-01-26 | Cordis Corporation | Balloon catheter with radioactive means |
US5876452A (en) * | 1992-02-14 | 1999-03-02 | Board Of Regents, University Of Texas System | Biodegradable implant |
US5891108A (en) * | 1994-09-12 | 1999-04-06 | Cordis Corporation | Drug delivery stent |
US5893840A (en) * | 1991-01-04 | 1999-04-13 | Medtronic, Inc. | Releasable microcapsules on balloon catheters |
US5945439A (en) * | 1992-08-17 | 1999-08-31 | Qlt Phototherapeutics, Inc. | Method for destroying or inhibiting growth of unwanted cells or tissues |
US5947889A (en) * | 1995-01-17 | 1999-09-07 | Hehrlein; Christoph | Balloon catheter used to prevent re-stenosis after angioplasty and process for producing a balloon catheter |
US5951586A (en) * | 1996-05-15 | 1999-09-14 | Medtronic, Inc. | Intraluminal stent |
US5951458A (en) * | 1996-02-29 | 1999-09-14 | Scimed Life Systems, Inc. | Local application of oxidizing agents to prevent restenosis |
US5972027A (en) * | 1997-09-30 | 1999-10-26 | Scimed Life Systems, Inc | Porous stent drug delivery system |
US5980566A (en) * | 1998-04-11 | 1999-11-09 | Alt; Eckhard | Vascular and endoluminal stents with iridium oxide coating |
US5980551A (en) * | 1997-02-07 | 1999-11-09 | Endovasc Ltd., Inc. | Composition and method for making a biodegradable drug delivery stent |
US5985307A (en) * | 1993-04-14 | 1999-11-16 | Emory University | Device and method for non-occlusive localized drug delivery |
US5993374A (en) * | 1997-06-17 | 1999-11-30 | Radiance Medical Systems, Inc. | Microcapsules for site-specific delivery |
US6001054A (en) * | 1998-05-19 | 1999-12-14 | Regulla; D. F. | Method and apparatus for differential energy application for local dose enhancement of ionizing radiation |
US6063101A (en) * | 1998-11-20 | 2000-05-16 | Precision Vascular Systems, Inc. | Stent apparatus and method |
US6069938A (en) * | 1998-03-06 | 2000-05-30 | Chornenky; Victor Ivan | Method and x-ray device using pulse high voltage source |
US6072038A (en) * | 1992-01-21 | 2000-06-06 | Board Of Regents, The University Of Texas System | Conjugates of texaphyrins |
US6071305A (en) * | 1996-11-25 | 2000-06-06 | Alza Corporation | Directional drug delivery stent and method of use |
US6095966A (en) * | 1997-02-21 | 2000-08-01 | Xrt Corp. | X-ray device having a dilation structure for delivering localized radiation to an interior of a body |
US6099561A (en) * | 1996-10-21 | 2000-08-08 | Inflow Dynamics, Inc. | Vascular and endoluminal stents with improved coatings |
US6108402A (en) * | 1998-01-16 | 2000-08-22 | Medtronic Ave, Inc. | Diamond vacuum housing for miniature x-ray device |
US6149574A (en) * | 1997-12-19 | 2000-11-21 | Radiance Medical Systems, Inc. | Dual catheter radiation delivery system |
US6176842B1 (en) * | 1995-03-08 | 2001-01-23 | Ekos Corporation | Ultrasound assembly for use with light activated drugs |
US6183409B1 (en) * | 1998-02-10 | 2001-02-06 | Implant Sciences Corporation | Soft x-ray emitting radioactive stent |
US6200257B1 (en) * | 1999-03-24 | 2001-03-13 | Proxima Therapeutics, Inc. | Catheter with permeable hydrogel membrane |
US6210393B1 (en) * | 1997-12-31 | 2001-04-03 | Pharmasonics, Inc. | Methods and systems for the inhibition of vascular hyperplasia |
US6390967B1 (en) * | 2000-09-14 | 2002-05-21 | Xoft Microtube, Inc. | Radiation for inhibiting hyperplasia after intravascular intervention |
US6398709B1 (en) * | 1999-10-19 | 2002-06-04 | Scimed Life Systems, Inc. | Elongated member for intravascular delivery of radiation |
US6400796B1 (en) * | 2001-01-30 | 2002-06-04 | Implant Sciences Corporation | X-ray emitting sources and uses thereof |
US6537195B2 (en) * | 2001-05-07 | 2003-03-25 | Xoft, Microtube, Inc. | Combination x-ray radiation and drug delivery devices and methods for inhibiting hyperplasia |
US20030103973A1 (en) * | 1994-02-10 | 2003-06-05 | Patricia Rockwell | Method for reducing tumor growth with VEGF antagonists combined with radiation and chemotherapy |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0813894B1 (en) | 1993-07-01 | 2001-12-05 | Schneider (Europe) GmbH | Medical appliances for the treatment of blood vessels by means of ionizing radiation |
DE59404200D1 (en) | 1993-08-13 | 1997-11-06 | Awm Werkzeugbau Ag | Spray nozzle |
EP0965363B1 (en) | 1994-06-24 | 2002-02-13 | Schneider (Europe) GmbH | Medical appliance for the treatment of a portion of body vessel by ionizing radiation |
US5683345A (en) | 1994-10-27 | 1997-11-04 | Novoste Corporation | Method and apparatus for treating a desired area in the vascular system of a patient |
AU4659096A (en) | 1995-01-30 | 1996-08-21 | Angiomedics Ii Incorporated | Photolytic drug delivery systems |
US6377846B1 (en) | 1997-02-21 | 2002-04-23 | Medtronic Ave, Inc. | Device for delivering localized x-ray radiation and method of manufacture |
US6799075B1 (en) | 1995-08-24 | 2004-09-28 | Medtronic Ave, Inc. | X-ray catheter |
US5735811A (en) | 1995-11-30 | 1998-04-07 | Pharmasonics, Inc. | Apparatus and methods for ultrasonically enhanced fluid delivery |
EP1009467A4 (en) | 1997-02-19 | 2001-07-25 | Condado Med Devices Corp | Multi-purpose catheters, catheter systems, and radiation treatment |
JP2003518392A (en) | 1998-03-11 | 2003-06-10 | バイオニュークレオニクス,インク. | Radioactivatable compositions suitable for the manufacture of implantable medical devices |
JP2002507930A (en) | 1998-04-27 | 2002-03-12 | ドゥブルル,ウィリアム,アール | Expandable support device with disease inhibitor and method of using same |
WO2000000238A1 (en) | 1998-06-26 | 2000-01-06 | Quanam Medical Corporation | Topoisomerase inhibitors for prevention of restenosis |
WO2000047197A2 (en) | 1999-02-12 | 2000-08-17 | Quanam Medical Corporation | Alkylating agents for treatment of cellular proliferation |
JP2000279524A (en) | 1999-03-30 | 2000-10-10 | Junichi Tanaka | Catheter |
US6195411B1 (en) | 1999-05-13 | 2001-02-27 | Photoelectron Corporation | Miniature x-ray source with flexible probe |
EP1057500A1 (en) | 1999-06-04 | 2000-12-06 | Radi Medical Technologies AB | Driving unit for intravascular radiation therapy |
EP1294306A1 (en) | 2000-06-05 | 2003-03-26 | Theragenics Corporation | A device for delivering a therapeutic dosage |
-
2001
- 2001-05-07 US US09/851,372 patent/US7018371B2/en not_active Expired - Fee Related
- 2001-05-07 US US09/850,728 patent/US7041046B2/en not_active Expired - Lifetime
-
2002
- 2002-05-07 WO PCT/US2002/014443 patent/WO2002089899A1/en not_active Application Discontinuation
-
2004
- 2004-12-10 US US11/009,501 patent/US20050124844A1/en not_active Abandoned
Patent Citations (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US34421A (en) * | 1862-02-18 | Improvement in channeling-tools for harness-makers | ||
US3976071A (en) * | 1974-01-07 | 1976-08-24 | Dynatech Corporation | Methods of improving control of release rates and products useful in same |
US4636195A (en) * | 1982-04-02 | 1987-01-13 | Harvey Wolinsky | Method and apparatus for removing arterial constriction |
US4832686A (en) * | 1986-06-24 | 1989-05-23 | Anderson Mark E | Method for administering interleukin-2 |
US4883666A (en) * | 1987-04-29 | 1989-11-28 | Massachusetts Institute Of Technology | Controlled drug delivery system for treatment of neural disorders |
US4897268A (en) * | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
US5061267A (en) * | 1987-12-22 | 1991-10-29 | Andreas Zeiher | Balloon catheter for rechanneling stenoses in body passages, in particular of coronary and peripheral arterial vessels |
US5059166A (en) * | 1989-12-11 | 1991-10-22 | Medical Innovative Technologies R & D Limited Partnership | Intra-arterial stent with the capability to inhibit intimal hyperplasia |
US5199939B1 (en) * | 1990-02-23 | 1998-08-18 | Michael D Dake | Radioactive catheter |
US5199939A (en) * | 1990-02-23 | 1993-04-06 | Dake Michael D | Radioactive catheter |
US5851231A (en) * | 1990-02-28 | 1998-12-22 | Medtronic, Inc. | Intralumenal drug eluting prosthesis |
US5997468A (en) * | 1990-02-28 | 1999-12-07 | Medtronic, Inc. | Intraluminal drug eluting prosthesis method |
US5545208A (en) * | 1990-02-28 | 1996-08-13 | Medtronic, Inc. | Intralumenal drug eluting prosthesis |
US5282785A (en) * | 1990-06-15 | 1994-02-01 | Cortrak Medical, Inc. | Drug delivery apparatus and method |
US5286254A (en) * | 1990-06-15 | 1994-02-15 | Cortrak Medical, Inc. | Drug delivery apparatus and method |
US5213561A (en) * | 1990-09-06 | 1993-05-25 | Weinstein Joseph S | Method and devices for preventing restenosis after angioplasty |
US5163952A (en) * | 1990-09-14 | 1992-11-17 | Michael Froix | Expandable polymeric stent with memory and delivery apparatus and method |
US5484584A (en) * | 1990-10-02 | 1996-01-16 | Board Of Regents, The University Of Texas System | Therapeutic and diagnostic use of modified polymeric microcapsules |
US5624372A (en) * | 1990-10-25 | 1997-04-29 | Omnitron International, Inc. | Source wire for localized internal irradiation of tissue |
US5090043A (en) * | 1990-11-21 | 1992-02-18 | Parker Micro-Tubes, Inc. | X-ray micro-tube and method of use in radiation oncology |
US5893840A (en) * | 1991-01-04 | 1999-04-13 | Medtronic, Inc. | Releasable microcapsules on balloon catheters |
US5354257A (en) * | 1991-01-29 | 1994-10-11 | Med Institute, Inc. | Minimally invasive medical device for providing a radiation treatment |
US5484384A (en) * | 1991-01-29 | 1996-01-16 | Med Institute, Inc. | Minimally invasive medical device for providing a radiation treatment |
US5318531A (en) * | 1991-06-11 | 1994-06-07 | Cordis Corporation | Infusion balloon catheter |
US5188595A (en) * | 1991-06-28 | 1993-02-23 | Laserscope | Method for enhanced retention of balloon catheter in body cavity |
US5411466A (en) * | 1991-09-05 | 1995-05-02 | Robert L. Hess | Apparatus for restenosis treatment |
US5302168A (en) * | 1991-09-05 | 1994-04-12 | Hess Robert L | Method and apparatus for restenosis treatment |
US5411550A (en) * | 1991-09-16 | 1995-05-02 | Atrium Medical Corporation | Implantable prosthetic device for the delivery of a bioactive material |
US5968092A (en) * | 1991-10-04 | 1999-10-19 | Boston Scientific Corporation | Method for making a biodegradable stent |
US5769883A (en) * | 1991-10-04 | 1998-06-23 | Scimed Life Systems, Inc. | Biodegradable drug delivery vascular stent |
US5551954A (en) * | 1991-10-04 | 1996-09-03 | Scimed Life Systems, Inc. | Biodegradable drug delivery vascular stent |
US5500013A (en) * | 1991-10-04 | 1996-03-19 | Scimed Life Systems, Inc. | Biodegradable drug delivery vascular stent |
US5464450A (en) * | 1991-10-04 | 1995-11-07 | Scimed Lifesystems Inc. | Biodegradable drug delivery vascular stent |
US6072038A (en) * | 1992-01-21 | 2000-06-06 | Board Of Regents, The University Of Texas System | Conjugates of texaphyrins |
US5876452A (en) * | 1992-02-14 | 1999-03-02 | Board Of Regents, University Of Texas System | Biodegradable implant |
US5656297A (en) * | 1992-03-12 | 1997-08-12 | Alkermes Controlled Therapeutics, Incorporated | Modulated release from biocompatible polymers |
US5591227A (en) * | 1992-03-19 | 1997-01-07 | Medtronic, Inc. | Drug eluting stent |
US5945439A (en) * | 1992-08-17 | 1999-08-31 | Qlt Phototherapeutics, Inc. | Method for destroying or inhibiting growth of unwanted cells or tissues |
US5342348A (en) * | 1992-12-04 | 1994-08-30 | Kaplan Aaron V | Method and device for treating and enlarging body lumens |
US5256141A (en) * | 1992-12-22 | 1993-10-26 | Nelson Gencheff | Biological material deployment method and apparatus |
US5419760A (en) * | 1993-01-08 | 1995-05-30 | Pdt Systems, Inc. | Medicament dispensing stent for prevention of restenosis of a blood vessel |
US5985307A (en) * | 1993-04-14 | 1999-11-16 | Emory University | Device and method for non-occlusive localized drug delivery |
US5679400A (en) * | 1993-04-26 | 1997-10-21 | Medtronic, Inc. | Intravascular stent and method |
US5837008A (en) * | 1993-04-26 | 1998-11-17 | Medtronic, Inc. | Intravascular stent and method |
US5643171A (en) * | 1993-05-04 | 1997-07-01 | Neocardia, Llc | Method and apparatus for uniform radiation treatment of vascular lumens |
US5540659A (en) * | 1993-07-15 | 1996-07-30 | Teirstein; Paul S. | Irradiation catheter and method of use |
US5543158A (en) * | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
US5735711A (en) * | 1993-08-27 | 1998-04-07 | Raychem Gmbh | Cable connector |
US5498227A (en) * | 1993-09-15 | 1996-03-12 | Mawad; Michel E. | Retrievable, shielded radiotherapy implant |
US5503613A (en) * | 1994-01-21 | 1996-04-02 | The Trustees Of Columbia University In The City Of New York | Apparatus and method to reduce restenosis after arterial intervention |
US20030103973A1 (en) * | 1994-02-10 | 2003-06-05 | Patricia Rockwell | Method for reducing tumor growth with VEGF antagonists combined with radiation and chemotherapy |
US5618266A (en) * | 1994-03-31 | 1997-04-08 | Liprie; Samuel F. | Catheter for maneuvering radioactive source wire to site of treatment |
US5566221A (en) * | 1994-07-12 | 1996-10-15 | Photoelectron Corporation | Apparatus for applying a predetermined x-radiation flux to an interior surface of a body cavity |
US5891108A (en) * | 1994-09-12 | 1999-04-06 | Cordis Corporation | Drug delivery stent |
US5649977A (en) * | 1994-09-22 | 1997-07-22 | Advanced Cardiovascular Systems, Inc. | Metal reinforced polymer stent |
US5616114A (en) * | 1994-12-08 | 1997-04-01 | Neocardia, Llc. | Intravascular radiotherapy employing a liquid-suspended source |
US5971909A (en) * | 1994-12-08 | 1999-10-26 | Neocardia Llc | Combined angioplasty and intravascular radiotherapy method and apparatus |
US5637113A (en) * | 1994-12-13 | 1997-06-10 | Advanced Cardiovascular Systems, Inc. | Polymer film for wrapping a stent structure |
US5700286A (en) * | 1994-12-13 | 1997-12-23 | Advanced Cardiovascular Systems, Inc. | Polymer film for wrapping a stent structure |
US5947889A (en) * | 1995-01-17 | 1999-09-07 | Hehrlein; Christoph | Balloon catheter used to prevent re-stenosis after angioplasty and process for producing a balloon catheter |
US5653736A (en) * | 1995-01-19 | 1997-08-05 | Cordis Corporation | Carrier balloon for a stent assembly with radiation-shielding capabilities |
US5569198A (en) * | 1995-01-23 | 1996-10-29 | Cortrak Medical Inc. | Microporous catheter |
US5800392A (en) * | 1995-01-23 | 1998-09-01 | Emed Corporation | Microporous catheter |
US6176842B1 (en) * | 1995-03-08 | 2001-01-23 | Ekos Corporation | Ultrasound assembly for use with light activated drugs |
US5609629A (en) * | 1995-06-07 | 1997-03-11 | Med Institute, Inc. | Coated implantable medical device |
US5681558A (en) * | 1995-11-30 | 1997-10-28 | Berlex Laboratories, Inc. | Method of using beta-interferons to treat restenosis |
US5951458A (en) * | 1996-02-29 | 1999-09-14 | Scimed Life Systems, Inc. | Local application of oxidizing agents to prevent restenosis |
US5951586A (en) * | 1996-05-15 | 1999-09-14 | Medtronic, Inc. | Intraluminal stent |
US5704908A (en) * | 1996-10-10 | 1998-01-06 | Genetronics, Inc. | Electroporation and iontophoresis catheter with porous balloon |
US6099561A (en) * | 1996-10-21 | 2000-08-08 | Inflow Dynamics, Inc. | Vascular and endoluminal stents with improved coatings |
US6071305A (en) * | 1996-11-25 | 2000-06-06 | Alza Corporation | Directional drug delivery stent and method of use |
US5863285A (en) * | 1997-01-30 | 1999-01-26 | Cordis Corporation | Balloon catheter with radioactive means |
US5980551A (en) * | 1997-02-07 | 1999-11-09 | Endovasc Ltd., Inc. | Composition and method for making a biodegradable drug delivery stent |
US5772642A (en) * | 1997-02-19 | 1998-06-30 | Medtronic, Inc. | Closed end catheter |
US6095966A (en) * | 1997-02-21 | 2000-08-01 | Xrt Corp. | X-ray device having a dilation structure for delivering localized radiation to an interior of a body |
US5843172A (en) * | 1997-04-15 | 1998-12-01 | Advanced Cardiovascular Systems, Inc. | Porous medicated stent |
US5993374A (en) * | 1997-06-17 | 1999-11-30 | Radiance Medical Systems, Inc. | Microcapsules for site-specific delivery |
US5972027A (en) * | 1997-09-30 | 1999-10-26 | Scimed Life Systems, Inc | Porous stent drug delivery system |
US6149574A (en) * | 1997-12-19 | 2000-11-21 | Radiance Medical Systems, Inc. | Dual catheter radiation delivery system |
US6210393B1 (en) * | 1997-12-31 | 2001-04-03 | Pharmasonics, Inc. | Methods and systems for the inhibition of vascular hyperplasia |
US6108402A (en) * | 1998-01-16 | 2000-08-22 | Medtronic Ave, Inc. | Diamond vacuum housing for miniature x-ray device |
US6183409B1 (en) * | 1998-02-10 | 2001-02-06 | Implant Sciences Corporation | Soft x-ray emitting radioactive stent |
US6069938A (en) * | 1998-03-06 | 2000-05-30 | Chornenky; Victor Ivan | Method and x-ray device using pulse high voltage source |
US5980566A (en) * | 1998-04-11 | 1999-11-09 | Alt; Eckhard | Vascular and endoluminal stents with iridium oxide coating |
US6001054A (en) * | 1998-05-19 | 1999-12-14 | Regulla; D. F. | Method and apparatus for differential energy application for local dose enhancement of ionizing radiation |
US6063101A (en) * | 1998-11-20 | 2000-05-16 | Precision Vascular Systems, Inc. | Stent apparatus and method |
US6200257B1 (en) * | 1999-03-24 | 2001-03-13 | Proxima Therapeutics, Inc. | Catheter with permeable hydrogel membrane |
US6398709B1 (en) * | 1999-10-19 | 2002-06-04 | Scimed Life Systems, Inc. | Elongated member for intravascular delivery of radiation |
US6390967B1 (en) * | 2000-09-14 | 2002-05-21 | Xoft Microtube, Inc. | Radiation for inhibiting hyperplasia after intravascular intervention |
US6400796B1 (en) * | 2001-01-30 | 2002-06-04 | Implant Sciences Corporation | X-ray emitting sources and uses thereof |
US6537195B2 (en) * | 2001-05-07 | 2003-03-25 | Xoft, Microtube, Inc. | Combination x-ray radiation and drug delivery devices and methods for inhibiting hyperplasia |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080009658A1 (en) * | 2006-06-19 | 2008-01-10 | Smith Peter C | Radiation therapy apparatus with selective shielding capability |
US20100280374A1 (en) * | 2007-09-19 | 2010-11-04 | Roberts Walter A | Direct Visualization Robotic Intra-Operative Radiation Therapy Applicator Device |
US8092370B2 (en) | 2007-09-19 | 2012-01-10 | Sriort, LLC | Direct visualization robotic intra-operative radiation therapy applicator device |
US8663210B2 (en) | 2009-05-13 | 2014-03-04 | Novian Health, Inc. | Methods and apparatus for performing interstitial laser therapy and interstitial brachytherapy |
US20140094777A1 (en) * | 2011-10-03 | 2014-04-03 | Gwendolyn Watanabe | Dual purpose balloon catheters |
US9737690B2 (en) * | 2011-10-03 | 2017-08-22 | Teleflex Medical Incorporated | Dual purpose balloon catheters |
Also Published As
Publication number | Publication date |
---|---|
US20020165424A1 (en) | 2002-11-07 |
US7018371B2 (en) | 2006-03-28 |
US7041046B2 (en) | 2006-05-09 |
WO2002089899A1 (en) | 2002-11-14 |
US20020165520A1 (en) | 2002-11-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7018371B2 (en) | Combination ionizing radiation and radiosensitizer delivery devices and methods for inhibiting hyperplasia | |
US6537195B2 (en) | Combination x-ray radiation and drug delivery devices and methods for inhibiting hyperplasia | |
US6390967B1 (en) | Radiation for inhibiting hyperplasia after intravascular intervention | |
US6422988B1 (en) | Combined angioplasty and intravascular radiotherapy method and apparatus | |
US5782740A (en) | Radiation dose delivery catheter with reinforcing mandrel | |
US6645135B1 (en) | Intravascular catheter device and method for simultaneous local delivery of radiation and a therapeutic substance | |
US6821242B1 (en) | Method and apparatus for treating a desired area in the vascular system of a patient | |
US5951458A (en) | Local application of oxidizing agents to prevent restenosis | |
US5851171A (en) | Catheter assembly for centering a radiation source within a body lumen | |
EP0741593B1 (en) | Apparatus to reduce restenosis after arterial intervention | |
US6224535B1 (en) | Radiation centering catheters | |
JP2002503986A (en) | Perfusion balloon and radioactive wire delivery system | |
US6547812B1 (en) | Radiation therapy using a radioactive implantable device and a radiosensitizer agent | |
US6402676B2 (en) | Tip configuration for radiation source wires | |
JPH1080497A (en) | Method combining angioplasty procedure and intravascular irradiation treatment and device therefor | |
EP0826393A1 (en) | Combined angioplasty and intravascular radiotherapy method and apparatus | |
WO1999002219A1 (en) | Method and system for the intramural delivery of radioactive agents | |
US6629920B2 (en) | Energy filtering system | |
WO1999040962A1 (en) | Radiation centering catheter with blood perfusion capability |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: XOFT, INC., CALIFORNIA Free format text: CHANGE OF NAME;ASSIGNOR:XOFT MICROTUBE, INC.;REEL/FRAME:015908/0584 Effective date: 20041012 |
|
AS | Assignment |
Owner name: EASTON CAPITAL PARTNERS, L.P., NEW YORK Free format text: SECURITY AGREEMENT;ASSIGNOR:XOFT, INC.;REEL/FRAME:025114/0354 Effective date: 20101008 |
|
AS | Assignment |
Owner name: XOFT, INC., CALIFORNIA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:EASTON CAPITAL PARTNERS, L.P.;REEL/FRAME:025558/0311 Effective date: 20101229 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: WESTERN ALLIANCE BANK, CALIFORNIA Free format text: SECURITY INTEREST;ASSIGNOR:XOFT, INC.;REEL/FRAME:052916/0197 Effective date: 20200330 |